

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 March 2002 (28.03.2002)

PCT

(10) International Publication Number
WO 02/24632 A2

(51) International Patent Classification⁷: **C07C 237/00**

Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(21) International Application Number: PCT/US01/27622

(74) Agents: **LEVY, David, J** et al.; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(22) International Filing Date:
6 September 2001 (06.09.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
60/233,144 18 September 2000 (18.09.2000) US

(71) Applicant (*for all designated States except US*): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLLINS, Jon, Loren** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **FIVUSH, Adam, M** [US/US]; 12023 Quarry Court, Fishers, IN 46038 (US). **MALONEY, Patrick, Reed** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **STEWART, Eugene, L** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **WILLSON, Timothy, Mark** [GB/US]; GlaxoSmithKline,

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/24632 A2

(54) Title: CHEMICAL COMPOUNDS

(57) Abstract: The invention relates to a compound of formula (I), wherein all variables are as defined herein, and pharmaceutically acceptable salts or solvates thereof. The compounds of formula (I) are useful as LXR agonists.

CHEMICAL COMPOUNDS

BACKGROUND OF THE INVENTION

5 The present invention relates to Liver X receptors (LXR). More particularly, the present invention relates to compounds useful as agonists for LXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same.

The orphan nuclear receptors, LXR α and LXR β (collectively LXR) play a role in the
10 maintenance of cholesterol balance. Peet *et al.*, *Curr. Opin. Genet. Dev.* 8:571-575 (1998). LXR is a transcription factor which regulates the expression of Cytochrome P450 7A (CYP7A). CYP7A catalyses a key step in the conversion of cholesterol to bile acid, which process results in the removal of cholesterol from the liver.


15 In addition, LXR binds to the ATP Binding Cassette Transporter-1 (ABC1) (also known as ABCA 1) gene and increases expression of the gene to result in increased ABC1 protein. ABC1 is a membrane bound transport protein which is involved in the regulation of cholesterol efflux from extrahepatic cells onto nascent HDL particles. Mutations in the ABC1 gene are responsible for genetic diseases that result in the
20 complete absence or low levels of HDL cholesterol and a concomitant highly increased risk of cardiovascular disease. See Brooks-Wilson *et al.*, *Nat. Genet.* 22:336-345 (1999); Bodzioch *et al.*, *Nat. Genet.* 22: 347-351 (1999); and Rust *et al.*, *Nat. Genet.* 22:352-355 (1999). ABC1 knockout mice homozygous for the mutation in the ABC1 gene have virtually no plasma HDL, whereas the heterozygotes produce 50% of the
25 HDL of wild type animals. See, Orso *et al.*, *Nat. Genet.* 24:192-196 (2000) and McNeish *et al.*, *Proc. Natl. Acad. Sci. USA* 97:4245-4250 (2000). ABC1 knockout mice also show increased cholesterol absorption. See, McNeish *et al.*, *Proc. Natl. Acad. Sci. USA* 97:4245-4250 (2000). Increased expression of ABC1 results in increased HDL cholesterol, decreased absorption of cholesterol, and increased removal of excess
30 cholesterol from extrahepatic tissues, including macrophages.

Accordingly compounds which function as LXR agonists would be useful in methods of increasing ABC1 expression, increasing HDL cholesterol and treating LXR mediated diseases and conditions such as cardiovascular disease.

5

SUMMARY OF THE INVENTION

According to a first aspect, the present invention provides compounds of formula (I):



15 wherein:

X is OH or NH₂;

p is 0-6;

each R¹ and R² are the same or different and are each independently selected from the group consisting of H, C₁-alkyl, C₁-alkoxy and C₁-thioalkyl;

20 Z is CH or N;

when Z is CH, k is 0-4;

when Z is N, k is 0-3;

each R³ is the same or different and is independently selected from the group

25 consisting of halo, -OH, C₁-alkyl, C₂-alkenyl, C₁-alkoxy, C₂-alkenyloxy, -S(O)_aR⁶, -NR⁷R⁸, -COR⁶, COOR⁶, R¹⁰COOR⁶, OR¹⁰COOR⁶, CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, 5-6 membered heterocycle, nitro, and cyano;

a is 0, 1 or 2;

R⁶ is selected from the group consisting of H, C₁-alkyl, C₁-alkoxy and C₂-alkenyl;

30 each R⁷ and R⁸ are the same or different and are each independently selected from the group consisting of H, C₁-alkyl, C₂-alkenyl, C₃-alkynyl;

R^9 is selected from the group consisting of H, C_{1-8} alkyl and $-NR^7R^8$;

R^{10} is C_{1-8} alkyl;

n is 2-8;

q is 0 or 1;

5 R^4 is selected from the group consisting of H, C_{1-8} alkyl, C_{1-8} alkenyl, and alkenyloxy;

Ring A is selected from the group consisting of C_{3-8} cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;

each ring B is the same or different and is independently selected from the group consisting of C_{3-8} cycloalkyl and aryl; and

10 pharmaceutically acceptable salts and solvates thereof.

In another aspect, the present invention provides compounds which are LXR agonists.

In a third aspect, the present invention provides compounds which upregulate

15 expression of ABC1.

In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I). The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier or diluent.

20

In another aspect, the present invention provides a method for the prevention or treatment of an LXR mediated disease or condition. The method comprises administering a therapeutically effective amount of a compound of formula (I). The present invention also provides compounds of formula (I) for use in therapy and
25 particularly for use in the prevention or treatment of an LXR mediated disease or condition. The present invention further provides the use of a compound of formula (I) for the preparation of a medicament for the prevention or treatment of an LXR mediated disease or condition.

30 In another aspect, the present invention provides a method for increasing reverse cholesterol transport. The method comprises administering a therapeutically effective amount of a compound of formula (I). The present invention also provides compounds

of formula (I) for increasing reverse cholesterol transport. The present invention further provides the use of compounds of formula (I) for the preparation of a medicament for increasing reverse cholesterol transport.

5 In another aspect, the present invention provides a method for inhibiting cholesterol absorption. The method comprises administering a therapeutically effective amount of a compound of formula (I). The present invention also provides compounds of formula (I) for inhibiting cholesterol absorption. The present invention further provides the use of compounds of formula (I) for the preparation of a medicament for
10 inhibiting cholesterol absorption.


In another aspect, the present invention provides a method for increasing HDL-cholesterol. The method comprises administering a therapeutically effective amount of a compound of formula (I). The present invention also provides compounds of
15 formula (I) for increasing HDL-cholesterol. The present invention further provides the use of compounds of formula (I) for the preparation of a medicament for increasing HDL-cholesterol.

In another aspect, the present invention provides a method for decreasing LDL-
20 cholesterol. The method comprises administering a therapeutically effective amount of a compound of formula (I). The present invention also provides compounds of formula (I) for decreasing LDL-cholesterol. The present invention further provides the use of compounds of formula (I) for the preparation of medicaments for decreasing LDL-cholesterol.


25 In another aspect, the present invention provides a radiolabeled compound of formula (I). In one embodiment, the compound of formula (I) is tritiated. The present invention also provides a method for identifying compounds which interact with LXR. The method comprises the step of specifically binding a radiolabeled compound of
30 formula (I) to the ligand binding domain of LXR. In another aspect, the present invention provides compounds identified using the assay methods described herein and methods for the prevention and treatment of an LXR-mediated disease or

condition by administering a compound identified using the assay methods described herein. The assay methods are also useful for identifying compounds which are LXR agonists, compounds which are selective LXR β agonists, compounds which upregulate ABC1, and compounds which are useful in methods for the treatment or prevention of LXR mediated diseases or conditions such as cardiovascular disease, including atherosclerosis.

In another aspect, the present invention provides a process for preparing compounds of formula (I). The process comprises reacting a solid phase-bound compound of formula (V):



wherein SP is solid phase and X⁰ is -O- or -NH-, and all other variables are as defined above in connection with compounds of formula (I);
with a compound of formula (VIII):




wherein all variables are as defined above in connection with compounds of formula (I).

The process may further comprise the additional step of cleaving the compound of formula (I) from the solid phase.

As another aspect, the present invention provides another process for preparing compounds of formula (I). The process comprises the steps of:


a) reacting a compound of formula (IV-A):



5

wherein X^1 is OR^{16} or NH_2 , where R^{16} is a protecting group, and all other variables are as defined above in connection with compounds of formula (I);

with a compound of formula (IX):




10

wherein all variables are as defined above in connection with compounds of formula (I)

15

to prepare a compound of formula (I-A):




20

and

b) in the embodiment wherein X^1 is OR^{16} , saponifying the compound of formula (I-A) to produce the compound of formula (I).

25 Either of the foregoing processes may comprise the additional step of converting a compound of formula (I) to a pharmaceutically acceptable salt or solvate thereof.

In another aspect, the present invention provides compounds of formula (I-A):



5

wherein

X^1 is OR^{16} or NH_2 , where R^{16} is a protecting group;

p is 0-6;

each R^1 and R^2 are the same or different and are each independently selected from the
10 group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₁₋₈thioalkyl;

Z is CH or N;

when Z is CH, k is 0-4;

when Z is N, k is 0-3;

each R^3 is the same or different and is independently selected from the group
15 consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy,
-S(O)_aR⁶, -NR⁷R⁸, -COR⁶, COOR⁶, R¹⁰COOR⁶, OR¹⁰COOR⁶, CONR⁷R⁸, -OC(O)R⁹,
-R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, 5-6 membered heterocycle, nitro, and cyano;

a is 0, 1 or 2;

R^6 is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and
20 C₂₋₈alkenyl;

each R^7 and R^8 are the same or different and are each independently selected
from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl, C₃₋₈alkynyl;

R^9 is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸;

R^{10} is C₁₋₈alkyl;

25 n is 2-8;

q is 0 or 1;

R^4 is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkenyl, and alkenyloxy;

Ring A is selected from the group consisting of C₃₋₈cycloalkyl, aryl, 4-8 membered
heterocycle, and 5-6 membered heteroaryl;

30 each ring B is the same or different and is independently selected from the group
consisting of C₃₋₈cycloalkyl and aryl; and

pharmaceutically acceptable salts and solvates thereof.

Further aspects of the present invention are described in the description of preferred embodiments, examples, and claims which follow.

5 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As used herein, the term "alkyl" refers to aliphatic straight or branched saturated hydrocarbon chains containing the specified number of carbon atoms. Examples of "alkyl" groups as used herein include but are not limited to methyl, ethyl, n-propyl, 10 isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octyl and the like. The term "alkyl" also refers to substituted alkyl wherein the substituents are selected from the group consisting of halo, -OR⁷ and -SR⁷, where R⁷ is H or C₁₋₈alkyl. This definition of "alkyl" is also applicable to terms such as "thioalkyl" which incorporate the "alkyl" term. Thus, a "thioalkyl" as used herein refers to the group S-R_a where R_a is "alkyl" as defined.

15 As used herein, the term "halo" refers to any halogen atom ie., fluorine, chlorine, bromine or iodine.

As used herein, the term "alkenyl" refers to an aliphatic straight or branched 20 unsaturated hydrocarbon chain containing at least one and up to three carbon-carbon double bonds. Examples of "alkenyl" groups as used herein include but are not limited to ethenyl and propenyl. The term "alkenyl" also refers to substituted alkenyl wherein the substituents are selected from the group consisting of halo, -OR⁷ and -SR⁷, where R⁷ is H or C₁₋₈alkyl.

25 As used herein, the term "alkoxy" refers to a group O-R_a where R_a is "alkyl" as defined above.

The term "alkenyloxy" as used herein refers to a group O-R_b where R_b is "alkenyl" as 30 defined above.

As used herein, the term "cycloalkyl" refers to a non-aromatic carbocyclic ring having the specified number of carbon atoms and up to three carbon-carbon double bonds. "Cycloalkyl" includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and bicyclic cycloalkyl groups such as bicycloheptane and bicyclo(2.2.1)heptene. The term "cycloalkyl" also refers to substituted cycloalkyl wherein the ring bears one or more substituents selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano, wherein a is 0, 1 or 2; R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl; each R⁷ and R⁸ is the same or different and is independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl and C₃₋₈alkynyl; R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸; and R¹⁰ is C₁₋₈alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the cycloalkyl ring will depend upon the size of ring. In one preferred embodiment, the cycloalkyl is a cyclohexyl which may be substituted as described above.

The term "aryl" as used herein refers to aromatic groups selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl. The term "aryl" also refers to substituted aryl wherein the phenyl or naphthyl ring bears one or more substituents selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano, wherein a is 0, 1 or 2; R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl; each R⁷ and R⁸ is the same or different and is independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl and C₃₋₈alkynyl; R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸; and R¹⁰ is C₁₋₈alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the aryl ring will depend upon the size of ring. For example, when the aryl ring is phenyl, the aryl ring may have up to 5 substituents selected from the foregoing list. One skilled in the art will readily be able to determine the maximum number of possible substituents for a 1-naphthyl or 2-

naphthyl ring. A preferred aryl ring according to the invention is phenyl, which may be substituted as described above.

The term "heterocycle" refers to a monocyclic saturated or unsaturated non-aromatic carbocyclic rings and fused bicyclic non-aromatic carbocyclic rings, having the
5 specified number of members in the ring and containing 1, 2 or 3 heteroatoms selected from N, O and S. Examples of particular heterocyclic groups include but are not limited to tetrahydrofuran, dihydropyran, tetrahydropyran, pyran, oxetane, thietane, 1,4-dioxane, 1,3-dioxane, 1,3-dioxalane, piperidine, piperazine,
10 tetrahydropyrimidine, pyrrolidine, morpholine, thiomorpholine, thiazolidine, oxazolidine, tetrahydrothiopyran, tetrahydrothiophene, and the like. The term "heterocycle" also refers to substituted heterocycles wherein the heterocyclic ring bears one or more substituents selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶,
15 -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano, wherein a is 0, 1 or 2; R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl; each R⁷ and R⁸ is the same or different and is independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl and C₃₋₈alkynyl; and R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸; and R¹⁰ is C₁₋₈alkyl. As
20 will be appreciated by those skilled in the art, the number of possible substituents on the heterocyclic ring will depend upon the size of ring. There are no restrictions on the positions of the optional substituents in the heterocycles. Thus, the term encompasses rings having a substituent attached to the ring through a heteroatom. One skilled in the art will readily be able to determine the maximum number and locations of
25 possible substituents for any given heterocycle. A preferred heterocycle according to the invention is piperidine, which may be substituted as described above.

The term "heteroaryl" refers to aromatic monocyclic heterocyclic rings and aromatic fused bicyclic rings having the specified number of members in the ring, having at
30 least one aromatic ring and containing 1, 2 or 3 heteroatoms selected from N, O and S. Examples of particular heteroaryl groups include but are not limited to furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole,

oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, and indazole. The term "heteroaryl" also refers to substituted heteroaryls wherein the heteroaryl ring bears one or more substituents selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano, wherein a is 0, 1 or 2; R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl; each R⁷ and R⁸ is the same or different and is independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl and C₃₋₈alkynyl; and R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸; and R¹⁰ is C₁₋₈alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the heteroaryl ring will depend upon the size of ring. There are no restrictions on the positions of the optional substituents in heteroaryls. Thus, the term encompasses rings having a substituent attached to the ring through a heteroatom. One skilled in the art will readily be able to determine the maximum number and locations of possible substituents for any given heteroaryl. A preferred heteroaryl according to the invention is pyridine, which may be substituted as described above.

As used herein, the term "protecting group" refers to suitable protecting groups useful for the synthesis of compounds of formula (I) wherein X is OH. Suitable protecting groups are known to those skilled in the art and are described in *Protecting Groups in Organic Synthesis*, 3rd Edition, Greene, T. W.; Wuts, P. G. M. Eds.; John Wiley & Sons: NY, 1999. Examples of preferred protecting groups include but are not limited to methyl, ethyl, benzyl, substituted benzyl, and tert-butyl. In one embodiment the protecting group is methyl.

Suitable pharmaceutically acceptable salts according to the present invention will be readily determined by one skilled in the art and will include, for example, acid addition salts prepared from inorganic acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulphonic, and sulfuric acids, and organic acids such as acetic, benzenesulphonic, benzoic, citric, ethanesulphonic, fumaric, gluconic, glycollic, isothionic, lactic, lactobionic, maleic, malic, methanesulphonic, succinic, *p*-

toluenesulfonic, salicylic, tartaric, and trifluoroacetic, formic, malonic, naphthalene-2-sulfonic, sulfamic, decanoic, orotic, 1-hydroxy-2-naphthoic, cholic, and pamoic. In one embodiment, the compounds of formula (I) are in the form of the hydrochloride salt.

5


When used in medicine, the salts of a compound of formula (I) should be pharmaceutically acceptable, but pharmaceutically unacceptable salts may conveniently be used to prepare the corresponding free base or pharmaceutically acceptable salts thereof.

10

As used herein, the term "solvate" is a crystal form containing the compound of formula (I) or a pharmaceutically acceptable salt thereof and either a stoichiometric or a non-stoichiometric amount of a solvent. Solvents, by way of example, include water, methanol, ethanol, or acetic acid. Hereinafter, reference to a compound of

15

The present invention provides compounds of formula I:



25

wherein:

X is OH or NH₂;

p is 0-6;



each R¹ and R² are the same or different and are each independently selected from the group consisting of H, C₁-alkyl, C₁-alkoxy and C₁-thioalkyl;

30

Z is CH or N;

when Z is CH, k is 0-4;

when Z is N, k is 0-3;

- each R^3 is the same or different and is independently selected from the group consisting of halo, $-OH$, $C_{1-8}alkyl$, $C_{2-8}alkenyl$, $C_{1-8}alkoxy$, $C_{2-8}alkenyloxy$, $-S(O)_aR^6$, $-NR^7R^8$, $-COR^6$, $COOR^6$, $R^{10}COOR^6$, $OR^{10}COOR^6$, $CONR^7R^8$, $-OC(O)R^9$, $-R^{10}NR^7R^8$, $-OR^{10}NR^7R^8$, 5-6 membered heterocycle, nitro, and cyano;
- 5 a is 0, 1 or 2;
- R^6 is selected from the group consisting of H, $C_{1-8}alkyl$, $C_{1-8}alkoxy$ and $C_{2-8}alkenyl$;
- each R^7 and R^8 are the same or different and are each independently selected from the group consisting of H, $C_{1-8}alkyl$, $C_{2-8}alkenyl$,
- 10 $C_{3-8}alkynyl$;
- R^9 is selected from the group consisting of H, $C_{1-8}alkyl$ and $-NR^7R^8$;
- R^{10} is $C_{1-8}alkyl$;
- n is 2-8;
- q is 0 or 1;
- 15 R^4 is selected from the group consisting of H, $C_{1-8}alkyl$, $C_{1-8}alkenyl$, and alkenyloxy;
-  refers to Ring A;
- Ring A is selected from the group consisting of $C_{3-8}cycloalkyl$, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;
-  refers to Ring B;
- 20 each ring B is the same or different and is independently selected from the group consisting of $C_{3-8}cycloalkyl$ and aryl; and
- pharmaceutically acceptable salts and solvates thereof.


- Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may
- 25 contain one or more asymmetric carbon atoms). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention. The present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centers are inverted.

30


In one preferred embodiment, the compounds of formula (I) are defined where X is OH. In another preferred embodiment, X is NH_2 .

In one embodiment, the compounds of formula (I) are defined wherein p is 0-3. In one preferred embodiment, p is 0 or 1. In one particular embodiment, p is 1.

Preferably, in the embodiments, where p is 1 or more, each R¹ and R² are the same or different and are each independently selected from the group consisting of H, C₁-alkyl, and C₁-alkoxy. In one preferred embodiment, each R¹ and R² are the same or different and are each independently selected from the group consisting of H and C₁-alkyl. In another preferred embodiment, each R¹ and R² are the same or different and are each independently selected from the group consisting of H and C₁-alkyl. In one particular embodiment, both R¹ and R² are H.

The group:  is preferably meta to the phenyl ether (when Z is CH) or pyridyl ether (when Z is N).

15 The group:



indicates a 6-membered aromatic ring which may contain up to 1 nitrogen atom (i.e., when Z is N) (i.e., the ring is phenyl or pyridine) and which may be substituted by one or more substituents R³. In one preferred embodiment, the compounds of formula (I) are defined where Z is CH. When Z is CH, k is 0-4, meaning that there can be up to 4 substituents R³ on the 6-membered aromatic ring. When Z is N, k is 0-3, meaning that there can be up to 3 substituents R³ on the 6-membered aromatic ring. In this embodiment, R³ is not attached to the N atom of the ring. Preferably, k is 0 or 1, more preferably 0.

In those embodiments wherein k is 1 or more, each R³ is preferably the same or different and is independently selected from the group consisting of halo and C₁-alkoxy. More preferably, each R³ is the same or different and is independently selected from the group consisting of F, Cl and methoxy.

In one embodiment, the compounds of formula (I) are defined wherein n is 2-4. In one preferred embodiment, n is 2 or 3. More preferably, n is 3.

Preferably, q is 1.

5

According to one embodiment, when q is 1, R⁴ is H or C₁₋₈alkyl. Preferably, when q is 1, R⁴ is H.

Ring A is selected from the group consisting of C₃₋₈cycloalkyl, aryl, 4-8 membered
10 heterocycle and 5-6 membered heteroaryl. By virtue of the definitions given above, for the terms "cycloalkyl," "aryl," "heterocycle," and "heteroaryl" this definition of Ring A also encompasses the foregoing rings optionally substituted with the substituents specified in the definitions above. In one embodiment, Ring A is selected from the group consisting of C₅₋₆cycloalkyl, aryl, 5-6 membered heterocycle and 5-6 membered
15 heteroaryl (each optionally substituted). In one preferred embodiment, Ring A is a aryl optionally substituted from 1 to 5 times, more preferably, from 1 to 4 times. In one particular preferred embodiment, Ring A is phenyl optionally substituted from 1 to 5 times (more preferably from 1 to 4 times) with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸,
20 -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano. In another preferred embodiment, Ring A is a 5-6 membered heterocycle optionally substituted from 1 to 8 times for a 5-membered heterocycle, and from 1 to 10 times for a 6-membered heterocycle with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹,
25 -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano. In one particular preferred embodiment, Ring A is a 6-membered heterocycle optionally substituted from 1 to 10 times (preferably from 1 to 4 times).

30 Specific examples of Ring A according to the present invention include phenyl or piperidine optionally substituted from 1 to 5 times with a substituent selected from the group consisting of halo, C₁₋₈alkyl, C₁₋₈alkoxy, -COOR⁶ and S(O)_aR⁶. More

- preferably, Ring A is phenyl or piperidine optionally substituted from 1 to 5 times with a substituent selected from the group consisting of F, Cl, -CF₃, -OCH₃, and -OCF₃. One specific preferred embodiment of compounds of formula (I) are defined wherein Ring A is phenyl optionally substituted from 1 to 4 times with a substituent selected from the group consisting of F, Cl, -CF₃, -OCH₃, and -OCF₃. Another specific embodiment of compounds of formula (I) is defined wherein Ring A is piperidine optionally substituted by -COOR⁶; and more preferably wherein the substituent -COOR⁶ is attached to the nitrogen of the piperidine ring and R⁶ is alkyl, e.g., methyl or ethyl.
- Each Ring B is the same or different and is independently selected from the group consisting of C₃₋₈cycloalkyl and aryl. By virtue of the definitions given above, for the terms "cycloalkyl" and "aryl" this definition of Ring B also encompasses the foregoing rings optionally substituted with the substituents specified in the definitions above. In one embodiment, both Rings B are phenyl optionally substituted from 1 to 5 times (more preferably from 1 to 3 times) with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano. In another embodiment, Rings B are cyclohexyl optionally substituted from 1 to 10 times (more preferably from 1 to 4 times) with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano. In yet another embodiment, one Ring B is phenyl optionally substituted from 1 to 5 times (more preferably from 1 to 3 times) with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano and the other Ring B is cyclohexyl optionally substituted from 1 to 10 times (more preferably from 1 to 4 times) with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano. In one particular embodiment, both Rings B are unsubstituted phenyl or unsubstituted cyclohexyl; more preferably unsubstituted phenyl.

The present invention contemplates and includes all combinations of the preferred groups defined above.

Preferred compounds of formula (I) include compounds selected the group consisting
5 of:

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}
phenyl) acetamide,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-
phenyl)acetic acid,

10 (3-{2-[(2,2-diphenylethyl)-(4-methoxybenzyl)amino]propoxy}phenyl)acetamide,

(3-{2-[(2,2-diphenylethyl)-(4-methoxybenzyl)amino]propoxy}phenyl)acetic acid,

2-(3-{3-[(2,2-diphenylethyl)(2-fluoro-4-methoxybenzyl)amino]propoxy}phenyl)
acetamide,

2-(3-{3-[(2,4-dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl) acetamide,

15 2-[3-(3-{(2,2-diphenylethyl)[4-fluoro-2-(trifluoromethyl)benzyl]amino}propoxy)
phenyl] acetamide,

2-(3-{3-[(2,3-dichlorobenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl) acetamide,

2-[3-(3-{(2,2-diphenylethyl)[3-(trifluoromethoxy)benzyl]amino}propoxy)phenyl]
acetamide,

20 2-(3-{3-[(2,2-diphenylethyl)(3-fluoro-4-methoxybenzyl)amino]propoxy}phenyl)
acetamide,

2-(3-{3-[(2,5-dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl) acetamide,

2-[3-(3-{(2,2-diphenylethyl)[3-(trifluoromethyl)benzyl]amino}propoxy)phenyl]
acetamide,

25 2-[3-(3-{(2,2-diphenylethyl)[2-fluoro-3-(trifluoromethyl)benzyl]amino}propoxy)
phenyl] acetamide;

Ethyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{2,2-diphenylethyl)amino]-1-
piperidinecarboxylate;

3-{3-[(1-Benzoyl-4-piperidinyl)-(2,2-diphenylethyl)amino]propoxy}benzamide;

30 3-{3-[(1-Acetyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy}benzamide;

Benzyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{2,2-diphenylethyl)amino]-1-
piperidinecarboxylate;

- 3-(3-{(2,2-Diphenylethyl)[1-(2-phenylethyl)-4-piperidinyl]amino}propoxy)benzamide;
 Ethyl 4-[{3-[3-(aminocarbonyl)phenoxy]propyl}{2-cyclohexyl-2-phenylethyl}amino]-
 1-piperidinecarboxylate;
 3-{3-[(1-Benzoyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-
 5 benzamide;
 3-{3-[(1-Acetyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-
 benzamide;
tert-Butyl 4-[{3-[3-(aminocarbonyl)phenoxy]propyl}{2-cyclohexyl-2-
 phenylethyl}amino]-1-piperidinecarboxylate;
 10 Benzyl 4-[{3-[3-(aminocarbonyl)phenoxy]propyl}{2-cyclohexyl-2-
 phenylethyl}amino]-1-piperidinecarboxylate;
 3-{3-[(1-Benzyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-
 benzamide;
 Ethyl 4-[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{2,2-diphenylethyl}amino]-1-
 15 piperidinecarboxylate;
 2-{3-[3-[(1-Benzoyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy}phenyl)-
 acetamide;
 2-{3-[3-[(1-Acetyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy}phenyl)-
 acetamide;
 20 *tert*-Butyl 4-[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{2,2-diphenylethyl}amino]-
 1-piperidinecarboxylate;
 Benzyl 4-[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{2,2-diphenylethyl}amino]-1-
 piperidinecarboxylate;
 2-[3-{3-[(2,2-Diphenylethyl)[1-(2-phenylethyl)-4-piperidinyl]amino}propoxy]phenyl]-
 25 acetamide;
 2-{3-[3-[(1-Benzoyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-
 phenyl)acetamide;
 2-{3-[3-[(1-Acetyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-
 phenyl)acetamide;
 30 Benzyl-4-[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{2-cyclohexyl-2-
 phenylethyl}amino]-1-piperidinecarboxylate;
 3-{3-[(3-Cyanobenzyl)(2,2-diphenylethyl)amino]propoxy}benzamide;

- 3-{3-[Cyclohexyl(2,2-diphenylethyl)amino]propoxy}benzamide;
 4-[[3-[3-(Aminocarbonyl)phenoxy]propyl]{2,2-diphenylethyl)amino}-1-
 piperidinecarboxamide;
 3-{3-[[1,3-Benzodioxol-4-ylmethyl](2,2-diphenylethyl)amino]propoxy}benzamide;
 5 3-{3-[[3,4-Dimethoxybenzyl](2,2-diphenylethyl)amino]propoxy}benzamide;
 3-{3-[(4-Cyanobenzyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}benzamide;
 3-{3-[(4-Cyanobenzyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}benzamide;
 2-(3-{3-[Cyclohexyl(2,2-diphenylethyl)amino]propoxy}phenyl)acetamide;
 2-(3-{3-[[3,4-Dimethoxybenzyl](2,2-diphenylethyl)amino]propoxy}phenyl)acetamide;
 10 3-{3-[(2-Cyclohexyl-2-phenylethyl)(3,4-dimethoxybenzyl)amino]propoxy}benzamide;
 3-{3-[(2,6-Dichlorobenzyl)(2,2-diphenylethyl)amino]propoxy}benzamide;
 3-{[[3-[3-(Aminocarbonyl)phenoxy]propyl]{2,2-diphenylethyl)amino)methyl}benzoic
 acid;
 4-[[3-[3-(Aminocarbonyl)phenoxy]propyl]{2,2-diphenylethyl)amino)methyl}benzoic
 15 acid;
 3-(3-{(2,2-Diphenylethyl)[(5-methoxy-1*H*-indol-3-yl)methyl]amino}propoxy)-
 benzamide;
 3-{3-[(2,2-Diphenylethyl)(4-methoxybenzyl)amino]propoxy}benzamide;
 3-{3-[[[1-Acetyl-1*H*-indol-3-yl)methyl](2,2-diphenylethyl)amino]propoxy}benzamide;
 20 Methyl 4-{[[3-[3-(aminocarbonyl)phenoxy]propyl]{2,2-diphenylethyl)amino)methyl}-
 benzoate;
 3-{3-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)(2,2-diphenylethyl)amino]propoxy}-
 benzamide;
 3-{3-[(2,2-Diphenylethyl)(4-pyridinylmethyl)amino]propoxy}benzamide;
 25 2-(3-{3-[(2-Cyclohexyl-2-phenylethyl)(3,4-difluorobenzyl)amino]propoxy}phenyl)
 acetamide;
 2-(3-{3-(2,2-Diphenylethyl)[[(6-chloro-1,3-benzodioxol-5-yl)methyl]amino]propoxy}-
 phenyl)acetamide;
 2-(3-{3-[(2,2-Diphenylethyl)(cyclohexylmethyl)amino]propoxy}phenyl) acetamide;
 30 2-(3-{3-[(2,2-Diphenylethyl)(bicyclo[2.2.1]hept-5-en-2-ylmethyl)amino]propoxy}-
 phenyl) acetamide;

- 2-(3-{3-[(2,2-diphenylethyl)(2,4-dimethoxy-5-pyrimidinyl)methyl]amino}propoxy}phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)(5-isopropyl-3-methyl-4-isoxazolyl)methyl]amino}propoxy}phenyl) acetamide;
- 5 2-(3-{3-[(2,2-Diphenylethyl)(3,4-dihydro-2H-pyran-2-ylmethyl)amino]propoxy}phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)(4-chloro-1H-pyrazol-3-yl)methyl]amino}propoxy}phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)([(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}propoxy}phenyl) acetamide;
- 10 2-(3-{3-[(2,2-Diphenylethyl)(2,6,6-trimethyl-1-cyclohexen-1-yl)ethyl]amino}propoxy}phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)(3-cyclohexen-1-ylmethyl)amino]propoxy}phenyl) acetamide;
- 15 2-[3-(3-{(2,2-Diphenylethyl)[(2E)-3-phenyl-2-propenyl]amino}propoxy)phenyl]acetamide;
- Ethyl 2-{[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{(2,2-diphenylethyl)amino}methyl}cyclopropanecarboxylate;
- 2-(3-{3-[(2,2-diphenylethyl)(1-cyclohexen-1-ylmethyl)amino]propoxy}phenyl) acetamide;
- 20 2-(3-{3-[(2,2-Diphenylethyl)(1H-benzimidazol-2-ylmethyl)amino]propoxy}phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)[(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)methyl]amino]propoxy}phenyl) acetamide; and
- 25 2-(3-{3-[(2,2-Diphenylethyl)(2-pyrrolidinylmethyl)amino]propoxy}phenyl) acetamide;
- and pharmaceutically acceptable salts and solvates thereof.

More preferred compounds of formula (I) include:

- 2-(3-{3-[(2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}phenyl) acetamide;
- 30 2-(3-{3-[(2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}phenyl)acetic acid;

- (3-{2-[(2,2-diphenylethyl)-(4-methoxybenzyl)amino]-propoxy}phenyl)acetamide;
 (3-{2-[(2,2-diphenylethyl)-(4-methoxybenzyl)amino]-propoxy}phenyl)acetic acid;
 2-(3-{3-[(2,2-diphenylethyl)(2-fluoro-4-methoxybenzyl)amino]propoxy}phenyl)
 acetamide;
- 5 2-(3-{3-[(2,4-dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl) acetamide;
 2-[3-(3-{(2,2-diphenylethyl)[4-fluoro-2-(trifluoromethyl)benzyl]amino}propoxy)
 phenyl] acetamide;
 2-(3-{3-[(2,3-dichlorobenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl) acetamide;
 2-[3-(3-{(2,2-diphenylethyl)[3-(trifluoromethoxy)benzyl]amino}propoxy)phenyl]
 10 acetamide;
 2-(3-{3-[(2,2-diphenylethyl)(3-fluoro-4-methoxybenzyl)amino]propoxy}phenyl)
 acetamide;
 2-(3-{3-[(2,5-dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl) acetamide;
 2-[3-(3-{(2,2-diphenylethyl)[3-(trifluoromethyl)benzyl]amino}propoxy)phenyl]
 15 acetamide; and
 2-[3-(3-{(2,2-diphenylethyl)[2-fluoro-3-(trifluoromethyl)benzyl]amino}propoxy)
 phenyl] acetamide;
 and pharmaceutically acceptable salts and solvates thereof.
- 20 Particularly preferred compounds of formula (I) include:
 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}
 phenyl) acetamide;
 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-
 phenyl)acetic acid;
- 25 (3-{2-[(2,2-diphenylethyl)-(4-methoxybenzyl)amino]-propoxy}phenyl)acetamide; and
 (3-{2-[(2,2-diphenylethyl)-(4-methoxybenzyl)amino]-propoxy}phenyl)acetic acid;
 and pharmaceutically acceptable salts and solvates thereof.
- One particularly preferred compound is 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl]
 30 (2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid and pharmaceutically
 acceptable salts and solvates thereof.

Another particularly preferred compound is 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy} phenyl) acetamide and pharmaceutically acceptable salts and solvates thereof.

- 5 Hereinafter all references to "compounds of formula (I)" refer to compounds of formula (I) as described above together with their pharmaceutically acceptable salts and solvates.

- Preferably, the compounds of formula (I) are LXR agonists. As used herein, the term
10 "LXR agonist" refers to compounds which achieve at least 50% activation of LXR relative to 24(S),25-epoxycholesterol, the appropriate positive control in the HTRF assay described below in Example 1. More preferably, the compounds of this invention achieve 100% activation of LXR in the HTRF assay.

- 15 More preferably, the compounds of formula (I) are selective LXR β agonists. As used herein, "selective LXR β agonist" refers to a LXR agonist whose EC₅₀ for LXR β is at least 2-3 fold, preferably, 5 fold and more preferably greater than 10 fold lower than its EC₅₀ for LXR α . EC₅₀ is the concentration at which a compound achieves 50% of its maximum activity.

- 20 In addition, preferably compounds of formula (I) will upregulate expression of ABC1. By upregulating expression of ABC1, is meant that the induction of ABC1 upon treatment of cells with compounds of formula (I) at a concentration less than or equal to 10 micromolar is greater than 2 fold greater than in the absence of compounds of
25 formula (I) in the assay described below in Example 3. Thus the compounds of formula (I) are useful in methods for upregulating expression of ABC1.

- The compounds of the formula (I) are useful for a variety of medicinal purposes. The compounds of formula (I) may be used in methods for the prevention or treatment of
30 LXR mediated diseases and conditions. LXR mediated diseases or conditions include cardiovascular disease including atherosclerosis, arteriosclerosis, hypercholesteremia, and hyperlipidemia. In particular, the compounds of formula (I) are useful in the

treatment and prevention of cardiovascular disease including arteriosclerosis and hypercholesteremia.

The present invention also provides a method for increasing reverse cholesterol transport. Lipoprotein metabolism is a dynamic process comprised of production of triglyceride rich particles from the liver (as VLDL), modification of these lipoprotein particles within the plasma (VLDL to IDL to LDL) and clearance of the particles from the plasma, again by the liver. This process provides the transport of triglycerides and free cholesterol to cells of the body. Reverse cholesterol transport is the proposed mechanism by which peripheral cholesterol is returned to the liver from extra-hepatic tissue. The process is carried out by HDL cholesterol. The combination of lipoprotein production (VLDL, HDL) from the liver, modification of particles (all) within the plasma and subsequent clearance back to the liver, accounts for the steady state cholesterol concentration of the plasma. Without wishing to be bound by any particular theory, it is currently believed that the compounds of formula (I) increase reverse cholesterol transport by raising the plasma level of HDL cholesterol and/or by increasing cholesterol efflux from the arteries.

The compounds of formula (I) are also useful for inhibiting cholesterol absorption, increasing HDL-cholesterol, and decreasing LDL-cholesterol.

The methods of the present invention are useful for the treatment of animals including mammals generally and particularly humans.

The methods of the present invention comprise the step of administering a therapeutically effective amount of the compound of formula (I). As used herein, the term "therapeutically effective amount" refers to an amount of the compound of formula (I) which is sufficient to achieve the stated effect. Accordingly, a therapeutically effective amount of a compound of formula (I) used in the method for the prevention or treatment of LXR mediated diseases or conditions will be an amount sufficient to prevent or treat the LXR mediated disease or condition. Similarly, a therapeutically effective amount of a compound of formula (I) for use in the method

of increasing reverse cholesterol transport will be an amount sufficient to increase reverse cholesterol transport.

The amount of a compound of formula (I) or pharmaceutically acceptable salt or solvate thereof, which is required to achieve the desired biological effect will depend on a number of factors such as the use for which it is intended, the means of administration, and the recipient, and will be ultimately at the discretion of the attendant physician or veterinarian. In general, a typical daily dose for the treatment of LXR mediated diseases and conditions in a human, for instance, may be expected to lie in the range of from about 0.01 mg/kg to about 100 mg/kg. This dose may be administered as a single unit dose or as several separate unit doses or as a continuous infusion. Similar dosages would be applicable for the treatment of other diseases, conditions and therapies including upregulating expression of ABC1, increasing reverse cholesterol transport, inhibiting cholesterol absorption, increasing HDL-cholesterol and decreasing LDL-cholesterol.

Thus in a further aspect the present invention provides pharmaceutical compositions comprising, as active ingredient, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. The composition may further comprise at least one pharmaceutical carrier or diluent. These pharmaceutical compositions may be used in the prophylaxis and treatment of the foregoing diseases or conditions and in cardiovascular therapies as mentioned above.

The carrier must be pharmaceutically acceptable and must be compatible with, i.e. not have a deleterious effect upon, the other ingredients in the composition. The carrier may be a solid or liquid and is preferably formulated as a unit dose formulation, for example, a tablet which may contain from 0.05 to 95% by weight of the active ingredient. If desired other physiologically active ingredients may also be incorporated in the pharmaceutical compositions of the invention.

Possible formulations include those suitable for oral, sublingual, buccal, parenteral (for example subcutaneous, intramuscular, or intravenous), rectal, topical including

transdermal, intranasal and inhalation administration. Most suitable means of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and on the nature of the active compound, but where possible, oral administration is preferred for the prevention and treatment of LXR mediated diseases and conditions.

Formulations suitable for oral administration may be provided as discrete units, such as tablets, capsules, cachets, lozenges, each containing a predetermined amount of the active compound; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions.

Formulations suitable for sublingual or buccal administration include lozenges comprising the active compound and, typically a flavored base, such as sugar and acacia or tragacanth and pastilles comprising the active compound in an inert base, such as gelatin and glycerine or sucrose acacia.

Formulations suitable for parenteral administration typically comprise sterile aqueous solutions containing a predetermined concentration of the active compound; the solution is preferably isotonic with the blood of the intended recipient. Additional formulations suitable for parenteral administration include formulations containing physiologically suitable co-solvents and/or complexing agents such as surfactants and cyclodextrins. Oil-in-water emulsions are also suitable formulations for parenteral formulations. Although such solutions are preferably administered intravenously, they may also be administered by subcutaneous or intramuscular injection.

Formulations suitable for rectal administration are preferably provided as unit-dose suppositories comprising the active ingredient in one or more solid carriers forming the suppository base, for example, cocoa butter.

Formulations suitable for topical or intranasal application include ointments, creams, lotions, pastes, gels, sprays, aerosols and oils. Suitable carriers for such formulations

include petroleum jelly, lanolin, polyethyleneglycols, alcohols, and combinations thereof.

Formulations of the invention may be prepared by any suitable method, typically by
5 uniformly and intimately admixing the active compound with liquids or finely divided solid carriers or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.

For example a tablet may be prepared by compressing an intimate mixture comprising
10 a powder or granules of the active ingredient and one or more optional ingredients, such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.

Suitable formulations for administration by inhalation include fine particle dusts or
15 mists which may be generated by means of various types of metered dose pressurized aerosols, nebulisers, or insufflators.

For pulmonary administration via the mouth, the particle size of the powder or droplets is typically in the range 0.5 -10 μ m, preferably 1-5 μ m, to ensure delivery into
20 the bronchial tree. For nasal administration, a particle size in the range 10-500 μ m is preferred to ensure retention in the nasal cavity.

Metered dose inhalers are pressurized aerosol dispensers, typically containing a suspension or solution formulation of the active ingredient in a liquefied propellant.
25 During use, these devices discharge the formulation through a valve adapted to deliver a metered volume, typically from 10 to 150 μ l, to produce a fine particle spray containing the active ingredient. Suitable propellants include certain chlorofluorocarbon compounds, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof. The
30 formulation may additionally contain one or more co-solvents, for example, ethanol surfactants, such as oleic acid or sorbitan trioleate, anti-oxidants and suitable flavouring agents.


Nebulisers are commercially available devices that transform solutions or suspensions of the active ingredient into a therapeutic aerosol mist either by means of acceleration of a compressed gas typically air or oxygen, through a narrow venturi orifice, or by means of ultrasonic agitation. Suitable formulations for use in nebulisers consist of the active ingredient in a liquid carrier and comprising up to 40% w/w of the formulation, preferably less than 20%w/w. The carrier is typically water or a dilute aqueous alcoholic solution, preferably made isotonic with body fluids by the addition of, for example, sodium chloride. Optional additives include preservatives if the formulation is not prepared sterile, for example, methyl hydroxy-benzoate, anti-oxidants, flavoring agents, volatile oils, buffering agents and surfactants.

Suitable formulations for administration by insufflation include finely comminuted powders which may be delivered by means of an insufflator or taken into the nasal cavity in the manner of a snuff. In the insufflator, the powder is contained in capsules or cartridges, typically made of gelatin or plastic, which are either pierced or opened *in situ* and the powder delivered by air drawn through the device upon inhalation or by means of a manually-operated pump. The powder employed in the insufflator consists either solely of the active ingredient or of a powder blend comprising the active ingredient, a suitable powder diluent, such as lactose, and an optional surfactant. The active ingredient typically comprises from 0.1 to 100 w/w of the formulation.

In addition to the ingredients specifically mentioned above, the formulations of the present invention may include other agents known to those skilled in the art of pharmacy, having regard for the type of formulation in issue. For example, formulations suitable for oral administration may include flavouring agents and formulations suitable for intranasal administration may include perfumes.

Compounds of the invention can be made according to any suitable method of organic chemistry. According to one method, compounds of formula (I) are prepared using a solid phase synthesis process as depicted in Scheme 1:

Scheme I




wherein X^0 is $-\text{O}-$ or $-\text{NH}-$, SP is solid phase, R^{15} is H or a protecting group, and all other variables are as defined above in connection with the description of compounds of formula (I).

In general, the reaction proceeds by a) reacting a solid phase-bound amine (where X in the compound of formula (I) is NH_2) or alcohol (where X in the compound of formula (I) is OH) with a compound of formula (II) and a coupling agent to produce a solid phase-bound compound of formula (III); b) in the embodiment wherein R^{15} is a protecting group, deprotecting the solid phase bound compound to prepare the compound of formula (III); c) alkylating the solid phase-bound compound of formula

- (III) with an alcohol of formula (VI) to produce a solid phase-bound compound of formula (IV); d) reacting the solid-phase-bound compound of formula (IV) with a compound of formula (VII) to produce the solid-phase bound compound of formula (V); and e) reacting the solid phase-bound compound of formula (V) with a compound of formula (VIII) under reductive amination conditions to produce the solid phase-bound compound of formula (I). The process may optionally further comprise the step of cleaving the solid phase-bound compound of formula (I) from the solid phase using conventional techniques such as treatment with mild acid.
- 10 Compounds of formula (II) are commercially available or can be prepared using conventional techniques such as those described in European Patent No. 303,742 published 22 February 1989, the subject matter of which is incorporated herein by reference in its entirety.
- 15 Suitable solid phase materials and coupling agents for use in the foregoing method are commercially available and will be readily apparent to those skilled in the art. Examples of suitable solid phase materials include polymer resins such as Rink Resin SS from Advanced Chemtech, and Argogel-MB-OH from Argonaut Technologies.
- 20 The alcohols of formula (VI), the compounds of formula (VII) and the compounds of formula (VIII) are all commercially available or can be prepared using conventional techniques.
- Compounds of formula (I) may also be prepared by an alternative method involving solution phase synthesis. The solution phase synthesis is depicted in Scheme (II) below.

Scheme II



wherein X^1 is OR^{16} or NH_2 , where R^{16} is a protecting group, and all other variables are as defined above in connection with the description of compounds of formula (I).

25

In general, the process comprises the steps of: a) alkylating a compound of formula (III-A) with an alcohol of formula (VI) to produce the compound of formula (IV-A), b) reacting a compound of formula (VII) with a compound of formula (VIII) under reductive amination conditions to produce a compound of formula (IX), c) reacting the compound of formula (IV-A) with the compound of formula (IX) to produce the compound of formula (I-A), and d) in the embodiment wherein X^1 is OR^{16} , saponifying the ester to produce compounds of formula (I) wherein X is OH .

30


The compounds of formula (III-A) are prepared by conventional esterification procedures, such as those described in A. Kreimeyer, *et al.*, *J. Med. Chem.* 1999, 42, 4394-4404.

5

The compounds of formula (VII) are commercially available or can be prepared using conventional techniques.

As another aspect, the present invention further provides compounds of formula (I-A)

10



15

wherein

X^1 is OR^{16} or NH_2 , where R^{16} is a protecting group;

p is 0-6;

20

each R^1 and R^2 are the same or different and are each independently selected from the group consisting of H, C_{1-8} alkyl, C_{1-8} alkoxy and C_{1-8} thioalkyl;

Z is CH or N;

when Z is CH, k is 0-4;

25

when Z is N, k is 0-3;

each R^3 is the same or different and is independently selected from the group consisting of halo, $-OH$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{1-8} alkoxy, C_{2-8} alkenyloxy, $-S(O)_aR^6$, $-NR^7R^8$, $-COR^6$, $COOR^6$, $R^{10}COOR^6$, $OR^{10}COOR^6$, $CONR^7R^8$, $-OC(O)R^9$, $-R^{10}NR^7R^8$, $-OR^{10}NR^7R^8$, 5-6 membered heterocycle, nitro, and cyano;

30

a is 0, 1 or 2;

R^6 is selected from the group consisting of H, C_{1-8} alkyl, C_{1-8} alkoxy and

C₂₋₈alkenyl;

each R⁷ and R⁸ are the same or different and are each independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl, C₃₋₈alkynyl;

5 R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸;
R¹⁰ is C₁₋₈alkyl;

n is 2-8;

q is 0 or 1;

10 R⁴ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkenyl, and alkenyloxy;

Ring A is selected from the group consisting of C₃₋₈cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;

each ring B is the same or different and is independently selected from the group consisting of C₃₋₈cycloalkyl and aryl; and

15 pharmaceutically acceptable salts and solvates thereof;

which are useful as intermediates for the preparation of compounds of formula (I).

Preferred compounds of formula (I-A) are defined according to the preferred definitions of variables as described for compounds of formula (I).

20 The present invention also provides radiolabeled compounds of formula (I).

Radiolabeled compounds of formula (I) can be prepared using conventional techniques. For example, radiolabeled compounds of formula (I) can be prepared by reacting the intermediate of formula (I-A) with tritium gas in the presence of an appropriate catalyst to produce radiolabeled compounds of formula (I).

25

In the embodiment wherein X¹ is -NH₂, the radiolabeled compounds of formula (I) are directly achieved using the foregoing method. In the embodiment wherein X¹ is OR¹⁶, the radiolabeled compound of formula (I-A) is saponified to produce the radiolabeled compounds of formula (I) wherein X is OH. In one preferred embodiment, the

30 compounds of formula (I) are tritiated.

The radiolabeled compounds of formula (I) are useful in assays for the identification of compounds which interact with LXR, and particularly for the identification of compounds which bind to LXR. Accordingly, the present invention provides an assay method for identifying compounds which interact with LXR, which method comprises the step of specifically binding the radiolabeled compound of formula (I) to the ligand binding domain of LXR. The method may further comprise the step of adding a test compound and measuring any decrease in the specific binding of the radiolabeled compound of formula (I) to the ligand binding domain of LXR (i.e., either LXR α or LXR β). Thus, suitable assay methods will include conventional competition binding assays. The radiolabeled compounds of formula (I) can be employed in LXR α and LXR β binding assays according to the methods described in Moore, L. B.; Parks, D. J.; Jones, S. A.; Bledsoe, R. K.; Consler, T. G.; Stimmel, J. B.; Goodwin, B.; Liddle, C.; Blanchard, S. G.; Willson, T. M.; Collins, J. L.; Kliewer, S. A. *J. Biol. Chem.* 2000, 275 (20), 15122-15127; Jones, S. A.; Moore, L. B.; Shenk, J. L.; Wisely, B. G.; Hamilton, G. A.; McKee, D. D.; Tomkinson, N. C. O.; LeCluyse, E. L.; Lambert, M. H.; Willson, T. M.; *et al. Mol. Endocrinol.* 2000, 14, 27-39; and Janowski, Bethany A.; Grogan, Michael J.; Jones, Stacey A.; Wisely, G. Bruce; Kliewer, Steven A.; Corey, Elias J.; Mangelsdorf, David J.. Structural requirements of ligands for the oxysterol liver X receptors LXR α and LXR β *Proc. Natl. Acad. Sci. U. S. A.* (1999), 96(1), 266-271, the subject matter of which is incorporated herein in their entirety. The same assay procedures using the radiolabeled compounds of formula (I) may also be used to identify compounds which are LXR agonists, compounds which are selective LXR β agonists and compounds which upregulate ABC1.

The present invention further comprises compounds identified using the foregoing assay method and methods of treating the various conditions and diseases described hereinabove, with a compound identified using the foregoing assay method. The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way, the present invention being defined by the claims.

In the examples, the following terms have the designated meaning: "pRSETa" is a known expression vector available from Invitrogen; "IPTG" means isopropyl β -D-thiogalactopyranoside; "PO₄" means phosphate; "PBS" means phosphate buffered saline; "TBS" means tris-buffered saline; EDTA means ethylenediamine tetraacetic acid; "DTT" means dithiothreitol; "FAF-BSA" means fatty-acid free bovine serum albumin; "SRC-1" means steroid receptor coactivator 1; "CS" means charcoal stripped; "nM" means nanomolar; " μ M" means micromolar; "mM" means millimolar; "pM" means picomolar; "mmol" means millimoles; "g" means grams; "ng" means nanograms; "mg/ml" means milligram per milliliter; " μ L" means microliters; and "mL" means milliliter.

Example 1: Assay for LXR β Activity

A modified polyhistidine tag (MKKGHHHHHHG) (SEQ ID No. 1) was fused in frame to the human LXR β ligand binding domain (amino acids 185-461 of Genbank accession number U07132) and subcloned into the expression vector pRSETa (Invitrogen) under the control of an IPTG inducible T7 promoter. The human LXR β ligand binding domain was expressed in E. coli strain BL21(DE3). Ten-liter fermentation batches were grown in Rich PO₄ media with 0.1 mg/mL Ampicillin at 25°C for 12 hours, cooled to 9°C and held at that temperature for 36 hours to a density of OD₆₀₀=14. At this cell density, 0.25 mM IPTG was added and induction proceeded for 24 hours at 9°C, to a final OD₆₀₀ = 16. Cells were harvested by centrifugation (20 minutes, 3500g, 4°C), and concentrated cell slurries were stored in PBS at -80°C.

Typically 25-50 g of cell paste is resuspended in 250-500 mL TBS, pH 8.0 (25mM Tris, 150 mM NaCl). Cells are lysed by passing 3 times through an APV Rannie MINI-lab homogenizer and cell debris is removed by centrifugation (30 minutes, 20,000g, 4°C). The cleared supernatant is filtered through coarse pre-filters, and TBS, pH 8.0, containing 500 mM imidazole is added to obtain a final imidazole concentration of 50mM. This lysate is loaded onto a column (XK-26, 10 cm) packed with Sepharose [Ni⁺⁺ charged] Chelation resin (available from Pharmacia) and pre-equilibrated with TBS pH 8.0/ 50mM imidazole. After washing to baseline absorbance with equilibration

buffer, the column is washed with approximately one column volume of TBS pH -8.0 containing 95mM imidazole. LXR β LBD(185-461) is eluted with a gradient from 50 to 500 mM imidazole. Column peak fractions are pooled immediately and diluted 5 fold with 25 mM Tris pH 8.0, containing 5% 1,2-propanediol, .5mM EDTA and 5mM DTT.

- 5 The diluted protein sample is then loaded onto a column (XK-16, 10cm) packed with Poros HQ resin (anion exchange). After washing to baseline absorbance with the dilution buffer the protein is eluted with a gradient from 50 -500 mM NaCl. Peak fractions are pooled and concentrated using Centri-prep 10K (Amicon) filter devices and subjected to size exclusion, using a column (XK-26, 90 cm) packed with Superdex-
10 75 resin (Pharmacia) pre-equilibrated with TBS, pH 8.0, containing 5 % 1,2-propanediol, 0.5mM EDTA and 5mM DTT.

- LXR β protein was diluted to approximately 10 μ M in PBS and five-fold molar excess of NHS-LC-Biotin (Pierce) was added in a minimal volume of PBS. This solution was
15 incubated with gentle mixing for 30 minutes at ambient room temperature. The biotinylation modification reaction was stopped by the addition of 2000x molar excess of Tris-HCl, pH 8. The modified LXR β protein was dialyzed against 4 buffer changes, each of at least 50 volumes, PBS containing 5mM DTT, 2mM EDTA and 2% sucrose. The biotinylated LXR β protein was subjected to mass spectrometric analysis to reveal
20 the extent of modification by the biotinylation reagent. In general, approximately 95% of the protein had at least a single site of biotinylation; and the overall extent of biotinylation followed a normal distribution of multiple sites, ranging from one to nine.

- 25 The biotinylated protein was incubated for 20-25 minutes at a concentration of 25nM in assay buffer (50mM KCl, 50mM Tris-pH8, 0.1mg/ml FAF-BSA, 10mM DTT) with equimolar amounts of streptavidin-AlloPhycoCyanin (APC, Molecular Probes). At the same time, the biotinylated peptide comprising amino acids 675-699 of SRC-1 (CPSSHSSLTERHKILHRLQLQEGSPS-CONH2) (SEQ ID No. 2) at a concentration of 25nM
30 was incubated in assay buffer with a 1/2 molar amount of streptavidin-labelled Europium (Wallac) for 20-25 minutes. After the initial incubations are completed, a 10 molar excess (250nM) of cold biotin was added to each of the solutions to block

the unattached streptavidin reagents. After 20 min at room temp, the solutions were mixed yielding a concentration of 12.5nM for the dye-labelled LXR β protein and SRC-1 peptide.

- 5 80 μ L of the protein/peptide mixture was added to each well of an assay plate containing 20 μ L of test compound. The final volume in each well was 0.1mL, and the concentration in the well for the dye-labelled protein and peptide was 10nM. The final test compound concentrations were between 56pM and 10 μ M. The plates were incubated at room temp in the dark for 4-12 hours and then counted on a Wallac
10 Victor fluorescent plate reader.

In this assay 1 μ M 24(S),25-epoxycholesterol gave a reading of 20000 fluorescence units over a background reading of 10000 fluorescence units.

15 Example 2: Assay for LXR α Activity

The assay for LXR α was run according to the procedures of Example 1, above using his-tagged LXR α ligand binding domain (amino acids 183-447 of Genbank accession number U22662 , with the 14th amino acid corrected to A from R).

- 20 In this assay 1 μ M 24(S),25-epoxycholesterol gave a reading of 20000 fluorescence units over a background reading of 10000 fluorescence units.

Example 3: Assay for ABC1 expression in macrophages


- RAW 264.7 cells, obtained from ATCC, were grown in Dulbecco's Modified Eagle Media
25 (DMEM, GIBCO) supplemented with 10% fetal bovine serum (FBS, Irvine Scientific), 2 mM glutamine (Irvine Scientific), 100 U penicillin/ml and 100 mg streptomycin/ml (Irvine Scientific). Cells were passaged routinely at 3-4 day intervals at a plating density of 1:3.

- 30 To assess the effects of test compounds on ABC1 expression, the cells were passaged into CS media (DMEM/F12 media without phenol red supplemented with 10%

- charcoal/dextran-treated FBS, 2 mM glutamine, 100 U penicillin/ml and 100 mg streptomycin/ml and 100 mM mevalonic acid lactone). Two days later, the media was replaced with fresh CS media containing 10 μ M of the test compound. After 24 hours, the media was removed and replaced with fresh CS media containing fresh drug. After 24 more hours, the media was aspirated and the cells lysed in Trizol reagent (GIBCO). RNA was then extracted according to manufacturer's instructions. The RNA was quantitated following RNase-free DNase treatment by using the Ribogreen System (Molecular Probes), and then diluted to 10ng/microL.
- 10 ABC1 expression was determined by quantitative PCR. TaqMan reactions were performed using the standard conditions on the ABI7700; 5.5mM MgCl₂, 1X TaqMan Buffer A, 300microM each dNTP, 20U RNase inhibitor, 12.5U MuLV RT;ase, 300nM of each primer, 200nM TaqMan probe, 1.25U AmpliTaq Gold, and 50ng RNA in a 50uL volume. The reaction conditions were 48°C for 30 minutes, 95°C for 10 minutes, and
- 15 40 cycles of 94°C for 15 seconds/60°C for 1 minute. The sequence of the primers and probe for mouse ABC1 (X75926) were: forward primer: AAGGGTTTCTTGCTCAGATTGTC (SEQ ID No. 3); reverse primer: TGCCAAAGGGTGGCACA (SEQ ID No. 4); probe oligo: CCAGCTGTCTTTGTTGCATTGCCC (SEQ ID No. 5). Results were analyzed on the ABI7700 using Sequence Detector v1.6 software provided with the machine. ABC1 expression
- 20 was calculated as fold induction in test compound-treated cells relative to vehicle-treated cells.

Example 4: 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}phenyl) acetamide

5



Rink Resin SS (1.0 g, 0.70 mmol, 0.70 mmol/g loading, Advanced ChemTech) was
 10 treated with 10 mL of 20% piperidine in dimethylformamide and rotated for 30
 minutes at room temperature. The resin was filtered, treated with 10 mL of 20%
 piperidine in dimethylformamide, and rotated for 1 hour. The resin was filtered,
 washed with dimethylformamide (2 x 15 mL) and dichloromethane (2 x 15 mL), and
 dried under house vacuum to give deprotected resin. Separately, a slurry of 3-
 15 hydroxyphenylacetic acid (0.53 g, 3.5 mmol) and [O-(7-azabenzotriazol-1-yl)-1,1,3,3-
 tetramethyluronium hexafluorophosphate] (1.33 g, 3.5 mmol) in 10 mL of anhydrous
 1-methyl-2-pyrrolidinone was treated with 2,6-lutidine (0.82 mL, 7.0 mmol) and
 stirred until the solid dissolved. The resulting solution was added to the deprotected
 resin, and the reaction was rotated for 15 hours. The resin was filtered, washed
 20 sequentially with dichloromethane (3 x 10 mL), dimethylformamide (3 x 10 mL),
 dichloromethane (2 x 10 mL), methanol (3 x 10 mL) and dichloromethane (3 x 10 mL),
 and dried under house vacuum overnight at 40°C. The dry resin was treated with 18
 mL of anhydrous toluene followed by triphenylphosphine (4.59 g, 17.5 mmol) and 3-
 bromo-1-propanol (2.43 g, 17.5 mmol). The resulting mixture was cooled to 0°C and
 25 treated in a dropwise fashion with a solution of diisopropyl azodicarboxylate (3.54 g,
 17.5 mmol) in 9 mL of anhydrous toluene. The reaction was allowed to slowly rise to
 room temperature and stirred for 15 hours. The resin was filtered, washed
 sequentially with dichloromethane (2 x 25 mL), dimethylformamide (2 x 25 mL),
 dichloromethane (3 x 25 mL), methanol (3 x 25 mL) and dichloromethane (3 x 25 mL),
 30 and dried under house vacuum overnight at 40°C. The bromide functionalized resin
 was treated with a solution of diphenethylamine (5.52g, 28.0 mmol) (or 2-cyclohexyl-
 2-phenylethanamine (28.0 mmol, PCT Publication No. W097/41846) for the cyclohexyl

examples) in 20 mL of anhydrous dimethylsulfoxide and rotated for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 25 mL), dimethylformamide (2 x 25 mL), dichloromethane (3 x 25 mL), methanol (3 x 25 mL) and dichloromethane (3 x 25 mL), and dried under house vacuum overnight at 40°C. A

5 small portion of the secondary amine resin (0.20 g, 0.165 mmol) was treated with a solution of 2-chloro-3-trifluoromethylbenzaldehyde (1.03 g, 4.90 mmol) in 9 mL of dimethylformamide. Solid sodium triacetoxyborohydride (1.05 g, 4.90 mmol) was added followed by 1 mL of glacial acetic acid, and the reaction was rotated for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 25 mL),


10 dimethylformamide (2 x 25 mL), dichloromethane (3 x 25 mL), methanol (3 x 25 mL) and dichloromethane (3 x 25 mL), and dried under house vacuum overnight at 40°C. The resin-bound product was treated with 5 mL of trifluoroacetic acid/dichloromethane (5/95) for 15 minutes, and the filtrate was collected. The cleavage procedure was repeated three times, and the filtrates were combined and

15 concentrated under reduced pressure. The crude product was purified by preparative thin layer chromatography (silica gel, 1 mm plates, Merck 20 x 20 cm silica gel 60 F₂₅₄) eluting with ethyl acetate:hexane:triethyl-amine (74:25:1) to give 28 mg (29% yield based on theoretical loading of secondary amine resin) of title compound as a viscous oil: ¹H NMR (CDCl₃, 400 MHz) δ 7.45 (d, 1 H, J = 7.6), 7.25– 7.11 (m, 12 H), 6.91 (t, 1 H, J = 7.7), 6.66 (s, 1 H), 6.64 (s, 1 H), 5.35 (bs, 1 H), 5.48 (bs, 1 H), 4.11 (t, 1 H, J = 7.7), 3.77 (s, 2 H), 2.68 (t, 2 H, J = 5.9), 3.53 (s, 2 H), 2.12 (d, 2 H, J = 7.7), 2.70 (t, 2 H, J = 6.6), 1.83 (t, 2 H, J = 6.2); MS (ESP+) *m/e* 582 (MH⁺); TLC (methanol:methylene chloride/3:97) R_f = 0.53.

20

Example 5: (3-{2-[(2,2-Diphenylethyl)-(4-methoxybenzyl)amino]-propoxy}phenyl)-acetamide


5



The title compound was prepared according to the procedures of **Example 4** to give 143 mg (43% yield based on theoretical loading of bromide functionalized resin) of a viscous oil: ¹H NMR (CDCl₃, 400MHz) δ 7.16-7.05 (m, 11 H), 6.93 (d, 2 H, J = 8.5), 6.81 (d, 1 H, J = 7.4), 6.63 (d, 2 H, J = 8.5), 6.53 (d, 1 H, J = 6.1), 6.63 (s, 1 H), 4.12 (t, 1 H, J = 7.8), 3.63 (s, 3 H), 3.49 (t, 2 H, J = 6.2), 3.44 (s, 2 H), 3.43 (s, 2 H), 2.95 (d, 2 H, J = 7.8), 2.50 (t, 2 H, J = 6.3), 1.68 (tt, 2 H, J = 6.2); MS (ESP+) *m/e* 509 (MH⁺); TLC (methanol:methylene chloride/3:97) R_f = 0.50.

15


Example 6: 2-(3-{3-[(2,2-Diphenylethyl)(2-fluoro-4-methoxybenzyl)amino]propoxy}phenyl) acetamide



The title compound was prepared according to the methods of **Example 4**: HPLC (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1% HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) t_R = 1.85 min; MS (ESP+) *m/e* 527 (MH⁺).


25

Example 7: 2-(3-{3-[(2,4-Dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl)acetamide



The title compound was prepared according to the procedures of Example 4: HPLC
5 (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1%
HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.45 min; MS (ESP+)
m/e 539 (MH⁺).


Example 8: 2-[3-(3-{(2,2-Diphenylethyl)[4-fluoro-2-(trifluoromethyl)benzyl]amino}
10 propoxy)phenyl] acetamide



The title compound was prepared according to the procedure of Example 4: HPLC
(Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1%
HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.41 min; MS (ESP+)
15 *m/e* 565 (MH⁺).


Example 9: 2-(3-{3-[(2,3-Dichlorobenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl)
acetamide

5




The title compound was prepared according to the procedure of Example 4: HPLC
10 (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1%
HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.09 min; MS (ESP+)
m/e 569 (MH⁺).

Example 10: 2-[3-(3-{(2,2-Diphenylethyl)[3-(trifluoromethoxy)benzyl]amino}
15 propoxy)phenyl] acetamide




The title compound was prepared according to the procedure of Example 4: HPLC
(Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1%
HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.69 min; MS (ESP+)
20 *m/e* 563 (MH⁺).

Example 11: 2-(3-{3-[(2,2-Diphenylethyl)(3-fluoro-4-methoxybenzyl)amino]propoxy}phenyl)acetamide



- The title compound was prepared according to the procedure of Example 4: HPLC (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1% HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) t_R = 1.99 min; MS (ESP+) m/e 527 (MH⁺).


Example 12: 2-(3-{3-[(2,5-Dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl)acetamide



- The title compound was prepared according to Example 4: ¹H NMR (CDCl₃, 400 MHz) δ 7.28-7.09 (m, 12 H), 6.91 (d, 1 H, J = 8.3), 6.86 (d, 1 H, J = 7.4), 6.4 (m, 2 H), 6.37 (s, 1 H), 6.25 (d, 1 H, J = 8.1), 4.15 (t, 1 H, J = 7.0), 3.79 (s, 3 H), 3.75-3.56 (m, 8 H), 3.01 (d, 2 H, J = 7.6), 2.61 (t, 2 H, J = 5.7), 1.80 (t, 2 H, J = 6); HPLC (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1% HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) t_R = 2.27 min; MS (ESP+) m/e 539 (MH⁺).

Example 13: 2-[3-(3-{(2,2-Diphenylethyl)[3-(trifluoromethyl)benzyl]amino}propoxy)phenyl] acetamide


5



The title compound was prepared according to the procedure of Example 4: HPLC
 10 (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1%
 HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.41 min; MS (ESP+) *m/e* 546 (MH⁺).

Example 14: 2-[3-(3-{(2,2-Diphenylethyl)[2-fluoro-3-(trifluoromethyl)benzyl]amino}
 15 propoxy)phenyl] acetamide


20



The title compound was prepared according to the procedure of Example 4: ¹H NMR
 (CDCl₃, 400 MHz) δ 7.37 (t, 1 H, J = 6.9), 7.23-7.11 (m, 12 H), 6.88 (t, 1 H, J = 6.9), 6.82
 (d, 1 H, J = 7.5), 6.64-6.61 (m, 2 H), 4.12 (t, 1 H, 7.8), 3.76-3.62 (m, 4 H), 3.52 (s, 2 H),
 25 3.09 (d, 2 H, J = 6), 2.67 (s, 2 H), 1.82 (s, 2 H); HPLC (Waters symmetry shield, RPq 3.5
 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1% HCOOH to 100% CH₃CN after 4
 min, flow rate = 0.8 mL/min) *t_R* = 2.44 min; MS (ESP+) *m/e* 565 (MH⁺).

Example 15: (3-{2-[(2,2-Diphenylethyl)-(4-methoxybenzyl)amino]-propoxy}phenyl)
acetic acid

5




Solid-phase synthesis:

- 10 Argogel-MB-OH (6.0g, 2.40mmol, Argonaut Technologies) was treated with a solution of (3-{[*tert*-butyl(dimethyl)silyl]oxy}phenyl)acetic acid (5.40g, 19.2 mmol, Eur. Pat. Appl. (1987) Application: EP 87-303742 19870428) in 50 mL of anhydrous dichloromethane followed by dicyclohexylcarbodiimide (4.16g, 19.2 mmol) and 4-dimethylaminopyridine (2.50 g, 19.2 mmol). After rotating at room temperature for
- 15 15 hours, the resin was filtered, washed sequentially with dichloromethane (2 x 25 mL), dimethylformamide (2 x 25mL), dichloromethane (3 x 25 mL), methanol (3 x 25 mL), dichloromethane (3 x 25 mL) and diethyl ether (2 x 25 mL). After drying under house vacuum overnight at 40°C, the resin was treated with 1.0 M tetrabutylammonium fluoride (24 mL, 23.4 mmol) in tetrahydrofuran, and the mixture
- 20 was rotated for 4 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 25 mL), dimethylformamide (2 x 25 mL), dichloromethane (3 x 25 mL), methanol (3 x 25 mL), and dichloromethane (3 x 25 mL) to give the deprotected phenol. The dry resin was treated with 90 mL of anhydrous toluene followed by triphenylphosphine (15.8 g, 60.0 mmol) and 3-bromo-1-propanol (8.4 g,
- 25 60.0 mmol). Upon cooling to 0°C, diisopropyl azodicarboxylate (12.1 g, 60.0 mmol) in 20 mL of anhydrous toluene was added in a dropwise fashion. The reaction was allowed to warm to room temperature and stirred for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 50 mL), dimethylformamide (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (2 x 50 mL) and dichloromethane (3 x 50
- 30 mL), and dried under house vacuum. The bromide functionalized resin was treated with a solution of diphenethylamine (25.0 g, 127 mmol) in 60 mL of anhydrous dimethylsulfoxide, and the reaction was rotated for 15 hours. The resin was filtered,

washed sequentially with dichloromethane (2 x 50 mL), dimethylformamide (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (3 x 50 mL) and dichloromethane (3 x 50 mL), and dried under house vacuum at 40°C. The secondary amine resin (5.75 g, 2.0 mmol) was treated with a solution of 4-methoxybenzaldehyde (5.44 g, 40.0 mmol) in 80 mL of 8% acetic acid in dimethylformamide. Solid sodium triacetoxyborohydride (8.5 g, 40.0 mmol) was added, and the reaction was rotated for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 50 mL), dimethylformamide (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (3 x 50 mL) and dichloromethane (3 x 50 mL), and dried under house vacuum overnight at 50°C.

The resin-bound product was treated with 30 mL of trifluoroacetic acid/dichloromethane (15/85) for 15 minutes, and the filtrate was collected. The cleavage procedure was repeated again, and the combined filtrates were concentrated under reduced pressure. The crude product was purified by preparative thin layer chromatography (silica gel, 1 mm plates, Merck 20 x 20 cm silica gel 60 F₂₅₄) eluting with methanol:dichloromethane (3:97) to afford 57 mg (6% yield based on theoretical loading of secondary amine resin) of the title compound as a viscous oil: ¹H NMR (CDCl₃, 400MHz) δ 7.18–7.03 (m, 10 H), 6.93 (d, 2 H, J = 8.6), 6.72 (d, 2 H, J = 7.6), 6.65 (d, 2 H, J = 8.6), 6.58 (s, 1 H), 6.49 (d, 1 H, J = 6.4), 4.71 (bs, 2 H), 4.11 (t, 1 H, J = 7.8), 3.65 (s, 3 H), 3.51 (t, 2 H, J = 6.2), 3.49 (s, 2 H), 3.40 (s, 2 H), 2.97 (d, 2 H, J = 7.8), 2.53 (t, 2 H, J = 6.5), 1.70 (tt, 2 H, J = 6.2); MS (ESP+) *m/e* 510 (MH⁺); TLC (CH₂Cl₂:MeOH/97:3) R_f = 0.13.

Example 16: 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid




The title compound was prepared according to the procedure of Example 15 to give 7.0 mg (5% yield based on theoretical loading of secondary amine resin) of a viscous

oil: ^1H NMR (CDCl_3 , 400MHz) δ 7.42 (d, 1 H, $J = 7.6$), 7.23–7.10 (m, 12 H), 6.85 (t, 2 H, $J = 8.1$), 6.63 (s, 1 H), 6.61 (s, 1 H), 4.11 (t, 1 H, $J = 7.8$), 3.75 (s, 2 H), 3.63 (t, 2 H, $J = 6.0$), 3.59 (s, 2 H), 2.12 (d, 2 H, $J = 7.8$), 2.67 (t, 2 H, $J = 6.6$), 1.81 (tt, 2 H, $J = 6.2$); MS (ESP+) m/e 582 (MH^+); TLC (EtOAc:hexanes/1:1) $R_f = 0.58$.

5

Example 17: (3-{2-[(2,2-Diphenylethyl)-(4-methoxybenzyl)amino]-propoxy}phenyl)acetic acid hydrochloride salt



10


Solution-phase synthesis:

A solution of methyl (3-{3-[(2,2-diphenylethyl)(4-methoxybenzyl)amino]propoxy}-phenyl)acetate (100 mg, 0.19 mmol) in 1.5 mL of tetrahydrofuran and 1 mL of water was treated with 1N aqueous LiOH (0.29 mL, 0.29 mmol). After stirring at room temperature for 2 hours, additional 1N aqueous LiOH (0.29 mL, 0.29 mmol) was added and stirring was continued for 2 hours. The reaction was neutralized with AcOH (66 μL , 0.58 mmol) and poured into $\text{H}_2\text{O}/\text{EtOAc}$. The layers were separated and the aqueous layer was extracted with EtOAc (3x). The combined organic layers were washed with brine (1x), dried over magnesium sulfate, filtered, and concentrated in vacuo. The crude material was purified by preparative thin layer chromatography (silica gel, 1 mm plates, Merck 20 x 20 cm silica gel 60 F₂₅₄) eluting with CH_2Cl_2 :MeOH (95:5) to afford an oil. The oil was dissolved in Et_2O and acidified with excess $\text{HCl}/\text{Et}_2\text{O}$. The reaction was concentrated in vacuo and dried under reduced pressure to give 155 mg (75% yield) of the title compound as a white solid: ^1H NMR ($\text{C}_5\text{D}_5\text{N}$, 400MHz) δ 7.40–7.00 (m, 15 H), 6.89 (d, 2 H, $J = 8.6$), 6.82 (dd, 1 H, $J = 8.1, 2.2$), 4.41 (t, 1 H, $J = 7.6$), 3.89 (s, 2 H), 3.67 (t, 2 H, $J = 6.4$), 3.64 (s, 3 H), 3.59 (s, 2 H), 3.13 (d, 2 H, $J = 7.6$), 2.64 (t, 2 H, $J = 6.7$), 1.90–1.80 (m, 2 H).

25

Example 18: 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid hydrochloride salt

5




The title compound was prepared in 56% yield from methyl (3-{3-[[2-chloro-3-(trifluoromethyl)benzyl]](2,2-diphenylethyl)amino]propoxy}phenyl)acetate according to the procedures of Example 17: ¹H NMR (C₅D₅N, 400MHz) δ 7.60-7.05 (m, 15 H), 7.01 (t, 1 H, J = 7.6), 6.84 (dd, 1 H, J = 8.4, 2.4), 4.32 (t, 1 H, J = 7.6), 3.89 (s, 2 H), 3.77 (s, 2 H), 3.71 (t, 2 H, J = 5.6), 3.16 (d, 2 H, J = 7.6), 2.65 (t, 2 H, J = 6.4), 1.88-1.78 (m, 2 H).

15

Example 19: Methyl (3-{3-[[2,2-diphenylethyl](4-methoxybenzyl)amino]propoxy}phenyl)acetate

20




A solution of methyl-[3-(3-bromopropoxy)phenyl]acetate (100 mg, 0.35 mmol) and *N*-(2,2-diphenylethyl)-*N*-(4-methoxybenzyl)amine (110 mg, 0.35 mmol) in 0.70 mL of acetonitrile was treated with solid K₂CO₃ (48 mg, 0.35 mmol). The reaction was heated to reflux and stirred 15 hours. Upon cooling to room temperature, the reaction was filtered through a pad of silica gel washing with EtOAc, and the filtrate was concentrated in vacuo. The crude product was purified by preparative thin layer chromatography (silica gel, 1 mm plates, Merck 20 x 20 cm silica gel 60 F₂₅₄) eluting with hexanes:EtOAc (6:1) to afford 100 mg (55% yield) of title compound as a viscous oil: ¹H NMR (CDCl₃, 400MHz) δ 7.25-7.10 (m, 10 H), 6.98 (d, 2 H, J = 8.6), 6.84 (d, 1 H,


30

J = 7.6), 6.70 (d, 2 H, J = 8.6), 6.65 (br s, 1 H), 6.61 (dd, 1 H, J = 8.4, 2.4), 4.17 (t, 1 H, J = 7.6), 3.76 (s, 3 H), 3.68 (s, 3 H), 3.60 (t, 2 H, J = 6.4), 3.59 (s, 2 H), 3.54 (s, 2 H), 3.03 (d, 2 H, J = 7.6), 2.60 (t, 2 H, J = 6.4), 1.79 (m, 2H); HPLC (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1% HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) t_R=2.49 min; MS (ESP+) *m/e* 524 (MH⁺); TLC (EtOAc:hexanes/1:1) R_f = 0.20.


Example 20: Methyl (3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy} phenyl)acetate



A solution of methyl [3-(3-bromopropoxy)phenyl]acetate (1.0 g, 3.48 mmole) and *N*-[2-chloro-3-(trifluoromethyl)benzyl]-2,2-diphenylethanamine (1.63 g, 4.18 mmole) in 20 mL of acetonitrile was treated with potassium carbonate (0.72 g, 5.2 mmol). The reaction mixture was heated to reflux and stirred for 4 days. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The crude product was purified by flash chromatography (silica gel cartridge, Biotage 32-63um, 60A) with 10% EtOAc:hexanes as the eluent to afford 1.69 g (81% yield) of the title compound as a viscous oil: ¹H NMR (CDCl₃, 400 MHz) δ 7.46-7.44 (d, 1 H, J = 7.7), 7.25-7.14 (m, 12 H), 6.91-6.84 (m, 2 H), 6.66-6.62 (m, 2 H), 4.15-4.09 (t, 1 H, J = 7.6), 3.78 (s, 1 H), 3.69-3.66 (m, 5 H), 3.59 (s, 2 H), 3.15-3.13 (d, 2 H, J = 7.7), 2.72-2.68 (t, 2 H, J = 6.6), 1.87-1.80 (m, 2 H); MS (ESP+) *m/e* 597 (MH⁺); TLC (hexanes:EtOAc/9:1) R_f = 0.36.

Example 21: Methyl [3-(3-bromopropoxy)phenyl]acetate

- 5 A solution of methyl 3-hydroxyphenylacetate (11.3 g, 0.068 mole) in 300 mL of anhydrous toluene was treated with 3-bromopropanol (12.2 g, 0.088 mol). Polymer bound triphenylphosphine (36.0 g, 0.108 mole, 3 mmol/g, Fluka Chemie) was then added, and the mixture reacted for 15 minutes. The reaction mixture was then cooled to 0°C and diisopropylazodicarboxylate (16.9 g, 0.084 mol) was added in a dropwise
- 10 fashion. After stirring at room temperature overnight, the crude reaction mixture was filtered and the solid washed with 100 mL toluene. After concentration of the filtrate in vacuo, the crude product was purified by column chromatography over silica gel (silica gel 60, EM Science) using 15% EtOAc:hexane as eluent to afford 15.8 g (81% yield) of the title compound as an oil: ¹H NMR (CDCl₃, 400 MHz) δ 7.23–7.19 (m, 1 H), 6.85–6.7 (m, 3), 4.09–4.06 (t, 2 H, J = 5.8), 3.67 (s, 3 H), 3.67–3.56 (m, 4 H), 2.32–2.26 (p, 2 H, J = 6.0) ; MS (ESP+) *m/e* 288 (MH⁺); TLC (hexanes:EtOAc/3:1) R_f = 0.68. Anal. (C₁₂H₁₅O₃Br) C, H, N.
- 15


Example 22: *N*-(2,2-Diphenylethyl)-*N*-(4-methoxybenzyl)amine

25

- A solution of 2,2-diphenethylamine (10.0 g, 50.7 mmol) and 98% p-anisaldehyde (6.17 mL, 50.7 mmol) in 80 mL of methanol and 40 mL of trimethylorthoformate was stirred at room temperature for 15 hours whereupon polymer-supported borohydride
- 30 resin (20.3 g, 55.8 mmol, 2.5 mmol/g, Aldrich) was added in one portion. After stirring at room temperature for 24 h, the reaction was filtered and the filtrate was concentrated in vacuo. The crude product was purified by column chromatography


over silica gel (silica gel 60, EM Science) using EtOAc:hexane/40:60 with 1% NH₄OH as the eluent to give 13.0 g (81% yield) of the title compound as an oil: ¹H NMR (CDCl₃, 400 MHz) δ 7.32–7.12 (m, 12 H), 4.22 (t, 1 H, J = 7.6), 3.78 (s, 3 H), 3.75 (s, 2 H), 3.21 (d, 2 H, J = 7.6); HPLC (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1% HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) t_R=1.67 min; MS (ESP+) m/e 318 (MH⁺); TLC (hexanes:EtOAc/4:1) R_f = 0.48.

Example 23: N-[2-Chloro-3-(trifluoromethyl)benzyl]-N-(2,2-diphenylethyl)amine



The title compound was prepared in 57% yield from 2,2-diphenethylamine and 2-chloro-3-trifluoromethylbenzaldehyde as in Example 22: ¹H NMR (CDCl₃, 400 MHz) δ 7.57 (d, 1 H, J = 8.0), 7.52 (d, 1 H, J = 7.6), 7.32–7.15 (m, 11 H), 4.20 (t, 1 H, J = 7.6), 3.94 (s, 2 H), 3.22 (d, 2 H, J = 7.6); HPLC (Waters symmetry shield, RPq 3.5 micron, 2.1 x 30 mm, 85:15/H₂O:CH₃CN with 0.1% HCOOH to 100% CH₃CN after 4 min, flow rate = 0.8 mL/min) t_R=2.39 min; MS (ESP+) m/e 390 (MH⁺); TLC (hexanes:EtOAc/4:1) R_f = 0.42.


Example 24: Ethyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl](2,2-diphenylethyl)-amino]-1-piperidinecarboxylate



The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.98 min; MS (ESP+) m/e 530 (MH⁺).

5 Example 25: 3-{3-[(1-Benzoyl-4-piperidiny)-(2,2-diphenylethyl)amino]propoxy}-benzamide

10




The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.99 min; MS (ESP+) m/e 562 (MH⁺).

15

Example 26: 3-{3-[(1-Acetyl-4-piperidiny)-(2,2-diphenylethyl)amino]propoxy}-benzamide


20



25 The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.70 min; MS (ESP+) m/e 500 (MH⁺).

Example 27: Benzyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{(2,2-diphenylethyl)-amino}-1-piperidinecarboxylate


5



10 The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.26 min; MS (ESP+) *m/e* 592 (MH⁺).

Example 28: 3-(3-{(2,2-Diphenylethyl)[1-(2-phenylethyl)-4-piperidinyl]amino}-propoxy)benzamide

15




20

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 1.90 min; MS (ESP+) *m/e* 562 (MH⁺).


25

Example 29: Ethyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl}{2-cyclohexyl-2-phenylethyl)amino]-1-piperidinecarboxylate



10 The title compound was prepared according to the procedures of **Example 4**: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.19 min; MS (ESP+) *m/e* 536 (MH⁺).


Example 30: 3-{3-[(1-Benzoyl-4-piperidiny)](2-cyclohexyl-2-phenylethyl)amino}-propoxy}benzamide



20

The title compound was prepared according to the procedures of **Example 4**: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.17 min; MS (ESP+) *m/e* 568 (MH⁺).

Example 31: 3-{3-[(1-Acetyl-4-piperidiny)(2-cyclohexyl-2-phenylethyl)amino]-
propoxy}benzamide




30

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.95 min; MS (ESP+) m/e 506 (MH⁺).

5 Example 32: *tert*-Butyl 4-[{3-[3-(aminocarbonyl)phenoxy]propyl}{2-cyclohexyl-2-phenylethyl}amino]-1-piperidinecarboxylate

10




15

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.41 min; MS (ESP+) m/e 564 (MH⁺).

Example 33: Benzyl 4-[{3-[3-(aminocarbonyl)phenoxy]propyl}{2-cyclohexyl-2-phenylethyl}amino]-1-piperidinecarboxylate

20




25

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.41 min; MS (ESP+) m/e 598 (MH⁺).

30


Example 34: 3-{3-[(1-Benzyl-4-piperidiny)(2-cyclohexyl-2-phenylethyl)amino]-propoxy}benzamide



5

The title compound was prepared according to the procedures of Example 4: HPLC
 10 (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100%
 MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.70 min; MS (ESP+) m/e 554 (MH⁺).

Example 35: Ethyl 4-[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{2,2-diphenylethyl}amino]-1-piperidinecarboxylate



15


20

The title compound was prepared according to the procedures of Example 4: HPLC
 (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100%
 MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.01 min; MS (ESP+) m/e 544 (MH⁺).

25

Example 36: 2-(3-{3-[(1-Benzoyl-4-piperidiny)](2,2-diphenylethyl)amino}-propoxy}phenyl)acetamide


5



The title compound was prepared according to the procedures of Example 4: HPLC
(Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100%
MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.04 min; MS (ESP+) m/e 576 (MH⁺).

Example 37: 2-(3-{3-[(1-Acetyl-4-piperidiny)](2,2-diphenylethyl)amino}propoxy}-phenyl)acetamide


15



The title compound was prepared according to the procedures of Example 4: HPLC
(Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100%
MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.74 min; MS (ESP+) m/e 514 (MH⁺).

Example 38: *tert*-Butyl 4-[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{2,2-diphenylethyl)amino]-1-piperidinecarboxylate


25



30

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.25 min; MS (ESP+) m/e 572 (MH⁺).


5 Example 39: Benzyl 4-[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}(2,2-diphenylethyl)amino]-1-piperidinecarboxylate



10

15 The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.30 min; MS (ESP+) m/e 606 (MH⁺).

20 Example 40: 2-[3-(3-{(2,2-Diphenylethyl)[1-(2-phenylethyl)-4-piperidiny]-2-amino}propoxy)phenyl]acetamide




25

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.67 min; MS (ESP+) m/e 576 (MH⁺).

30

Example 41: 2-(3-{3-[(1-Benzoyl-4-piperidiny)](2-cyclohexyl-2-phenylethyl)-
amino]propoxy}phenyl)acetamide


5



The title compound was prepared according to the procedures of Example 4: HPLC
 10 (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100%
 MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.23 min; MS (ESP+) m/e 582 (MH⁺).

Example 42: 2-(3-{3-[(1-Acetyl-4-piperidiny)](2-cyclohexyl-2-phenylethyl)-
amino]propoxy}phenyl)acetamide


15



20 The title compound was prepared according to the procedures of Example 4: HPLC
 (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100%
 MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.95 min; MS (ESP+) m/e 520 (MH⁺).


Example 43: Benzyl-4-[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{(2-cyclohexyl-2-
 25 phenylethyl)amino]-1-piperidinecarboxylate

30



The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.44 min; MS (ESP+) m/e 612 (MH⁺).


5 Example 44: 3-{3-[(3-Cyanobenzyl)(2,2-diphenylethyl)amino]propoxy}benzamide



10

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.40 min; MS (ESP+) m/e 490 (MH⁺).


15 Example 45: 3-{3-[Cyclohexyl(2,2-diphenylethyl)amino]propoxy}benzamide



20

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.99 min; MS (ESP+) m/e 457 (MH⁺).


25 Example 46: 4-{3-[3-(Aminocarbonyl)phenoxy]propyl}{2,2-diphenylethyl)amino]-1-piperidinecarboxamide



30

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 1.60 min; MS (ESP+) m/e 501 (MH⁺).

5 Example 47: 3-{3-[(1,3-Benzodioxol-4-ylmethyl)(2,2-diphenylethyl)amino]-propoxy}benzamide




10

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.12 min; MS (ESP+) m/e 509 (MH⁺).

15

Example 48: 3-{3-[(3,4-Dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}-benzamide




20

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.00 min; MS (ESP+) m/e 525 (MH⁺).

25


Example 49: 3-{3-[(4-Cyanobenzyl)(2-cyclohexyl-2-phenylethyl)amino]-propoxy}benzamide



30

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.45 min; MS (ESP+) m/e 496 (MH⁺).


5 Example 50: 3-{3-[[4-Cyanobenzyl](2-cyclohexyl-2-phenylethyl)amino]-propoxy}benzamide



10

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.45 min; MS (ESP+) m/e 496 (MH⁺).


15 Example 51: 2-{3-[3-(Cyclohexyl(2,2-diphenylethyl)amino)propoxy]-phenyl}acetamide



20

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.07 min; MS (ESP+) m/e 471 (MH⁺).

Example 52: 2-{3-[3-[(3,4-Dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy]-phenyl}acetamide




5

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.06 min; MS (ESP+) *m/e* 539 (MH⁺).

10

Example 53: 3-{3-[(2-Cyclohexyl-2-phenylethyl)(3,4-dimethoxybenzyl)amino]-propoxy}benzamide




15

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.62 min; MS (ESP+) *m/e* 531 (MH⁺).

20

Example 54: 3-{3-[(2,6-Dichlorobenzyl)(2,2-diphenylethyl)amino]propoxy}benzamide




25

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 3.04 min; MS (ESP+) *m/e* 534 (MH⁺).


30

Example 55: 3-{{[3-[3-(Aminocarbonyl)phenoxy]propyl}{(2,2-diphenylethyl)-amino]methyl}benzoic acid




The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.00 min; MS (ESP+) *m/e* 509 (MH⁺).

Example 56: 4-{{[3-[3-(Aminocarbonyl)phenoxy]propyl}{(2,2-diphenylethyl)-amino]methyl}benzoic acid




The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.05 min; MS (ESP+) *m/e* 509 (MH⁺).


Example 57: 3-(3-{(2,2-Diphenylethyl)[(5-methoxy-1*H*-indol-3-yl)methyl]amino}-propoxy)benzamide




The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.12 min; MS (ESP+) *m/e* 534 (MH⁺).

Example 58: 3-{3-[(2,2-Diphenylethyl)(4-methoxybenzyl)amino]propoxy}benzamide

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.10 min; MS (ESP+) m/e 495 (MH⁺).

Example 59: 3-{3-[[1-Acetyl-1H-indol-3-yl)methyl](2,2-diphenylethyl)amino]-propoxy}benzamide


The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.27 min; MS (ESP+) m/e 546 (MH⁺).

Example 60: Methyl 4-{[{3-[3-(aminocarbonyl)phenoxy]propyl}{2,2-diphenylethyl)-amino]methyl}benzoate

The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) t_R = 2.36 min; MS (ESP+) m/e 523 (MH⁺).

Example 61: 3-{3-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)(2,2-diphenylethyl)-amino]propoxy}benzamide

5




The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.06 min; MS (ESP+) *m/e* 523 (MH⁺).

10

Example 62: 3-{3-[(2,2-Diphenylethyl)(4-pyridinylmethyl)amino]propoxy}benzamide

15




The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.12 min; MS (ESP+) *m/e* 466 (MH⁺).

20

Example 63: 2-(3-{3-[(2-Cyclohexyl-2-phenylethyl)(3,4-difluorobenzyl)amino]-propoxy}phenyl)acetamide

25




The title compound was prepared according to the procedures of Example 4: HPLC (Waters symmetry shield, C8, 3.5 micron, 2.1 x 50 mm, 85:15/H₂O:MeOH to 100% MeOH after 4 min, flow rate = 0.8 mL/min) *t_R* = 2.12 min; MS (ESP+) *m/e* 521 (MH⁺).

30

Example 64: 2-(3-{3-(2,2-Diphenylethyl)[[(6-chloro-1,3-benzodioxol-5-yl)methyl]-
amino]propoxy}phenyl)acetamide

5




The title compound was prepared according to the methods of Example 4: HPLC
(Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH
after 3 min, flow rate = 0.8 mL/min) *t_R* = 4.04 min; MS (ESP+) *m/e* 557 (MH⁺).

10

Example 65: 2-(3-{3-[(2,2-Diphenylethyl)(cyclohexylmethyl)amino]propoxy}phenyl)
acetamide

15




The title compound was prepared according to the methods of Example 4: HPLC
(Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH
after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.56 min; MS (ESP+) *m/e* 485 (MH⁺).

20

Example 66: 2-(3-{3-[(2,2-Diphenylethyl)(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-
amino]propoxy}phenyl) acetamide

25




The title compound was prepared according to the methods of Example 4: HPLC
(Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH
after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.49 min; MS (ESP+) *m/e* 495 (MH⁺).

30

Example 67: 2-(3-{3-[(2,2-diphenylethyl)(2,4-dimethoxy-5-pyrimidinyl)methyl]amino}propoxy}phenyl)acetamide


5



The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.45 min; MS (ESP+) *m/e* 541 (MH⁺).

Example 68: 2-(3-{3-[(2,2-Diphenylethyl)(5-isopropyl-3-methyl-4-isoxazolyl)methyl]amino}propoxy}phenyl)acetamide

15




20

The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 4.45 min; MS (ESP+) *m/e* 526 (MH⁺).

Example 69: 2-(3-{3-[(2,2-Diphenylethyl)(3,4-dihydro-2H-pyran-2-ylmethyl)amino]propoxy}phenyl)acetamide


30



The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.53 min; MS (ESP+) *m/e* 485 (MH⁺).

5 Example 70: 2-(3-{3-[(2,2-Diphenylethyl)(4-chloro-1H-pyrazol-3-yl)methyl]amino}propoxy}phenyl)acetamide

10




The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.43 min; MS (ESP+) *m/e* 503 (MH⁺).

15

15 Example 71: 2-(3-{3-[(2,2-Diphenylethyl)((7-methoxy-1,3-benzodioxol-5-yl)methyl)amino]propoxy}phenyl)acetamide

20




The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.51 min; MS (ESP+) *m/e* 553 (MH⁺).

25

Example 72: 2-(3-{3-[(2,2-Diphenylethyl)-(2,6-trimethyl-1-cyclohexen-1-yl)ethyl]amino}propoxy}phenyl) acetamide


5



The title compound was prepared according to the methods of Example 4: HPLC
(Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH
after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.97 min; MS (ESP+) *m/e* 540 (MH⁺).

Example 73: 2-(3-{3-[(2,2-Diphenylethyl)(3-cyclohexen-1-ylmethyl)amino]-propoxy}phenyl) acetamide


15



The title compound was prepared according to the methods of Example 4: HPLC
(Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH
after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.51 min; MS (ESP+) *m/e* 483 (MH⁺).

Example 74: 2-[3-(3-{(2,2-Diphenylethyl)[(2*E*)-3-phenyl-2-propenyl]amino}propoxy)phenyl]acetamide


25



30

The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.59 min; MS (ESP+) *m/e* 505 (MH⁺).

5 Example 75: Ethyl 2-{{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{2,2-diphenylethyl}amino)methyl}cyclopropanecarboxylate




10

The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.35 min; MS (ESP+) *m/e* 515 (MH⁺).

15

Example 76: 2-(3-{3-[(2,2-diphenylethyl)(1-cyclohexen-1-ylmethyl)amino]propoxy}phenyl) acetamide




20

The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.55 min; MS (ESP+) *m/e* 483 (MH⁺).

25

Example 77: 2-(3-{3-[(2,2-Diphenylethyl)(1*H*-benzimidazol-2-ylmethyl)amino]-propoxy}phenyl) acetamide




5

The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.77 min; MS (ESP+) *m/e* 519 (MH⁺).

10

Example 78: 2-(3-{3-[(2,2-Diphenylethyl)[(1,3-dimethyl-2-oxo-2,3-dihydro-1*H*-benzimidazol-5-yl)methyl]amino]propoxy}phenyl) acetamide




15

The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.41 min; MS (ESP+) *m/e* 563 (MH⁺).

20

Example 79: 2-(3-{3-[(2,2-Diphenylethyl)(2-pyrrolidinylmethyl)amino]propoxy}phenyl) acetamide











25









The title compound was prepared according to the methods of Example 4: HPLC (Waters symmetry shield, C8 3.0 micron, 2 x 50 mm, 85:15/H₂O:CH₃OH to 100% CH₃OH after 3 min, flow rate = 0.8 mL/min) *t_R* = 3.48 min; MS (ESP+) *m/e* 472 (MH⁺).









30









Examples 80-283









The following compounds were synthesized according to the methods of Example 4.









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 80 |  | 2.16 | 531 | 84 |  | 1.81 | 541 |
| 81 |  | 1.82 | 555 | 85 |  | 2.29 | 533 |
| 82 |  | 2.21 | 523 | 86 |  | 2.16 | 493 |
| 83 |  | 2.23 | 523 | 87 |  | 2.28 | 543 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 88 |  | 2.16 | 541 | 92 |  | 2.39 | 581 |
| 89 |  | 2.08 | 552 | 93 |  | 2.46 | 565 |
| 90 |  | 1.91 | 551 | 94 |  | 1.36 | 499 |
| 91 |  | 2.16 | 515 | 95 |  | 1.96 | 569 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 96 |  | 2.34 | 537 | 100 |  | 1.83 | 502 |
| 97 |  | 2.04 | 525 | 101 |  | 2.4 | 581 |
| 98 |  | 2.23 | 499 | 102 |  | 1.97 | 497 |
| 99 |  | 2.26 | 529 | 103 |  | 1.8 | 536 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 104 |  | 1.95 | 555 | 108 |  | 2.41 | 547 |
| 105 |  | 1.94 | 561 | 109 |  | 2.47 | 569 |
| 106 |  | 2.26 | 493 | 110 |  | 2.09 | 486 |
| 107 |  | 2.02 | 502 | 111 |  | 1.78 | 522 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 112 |  | 2.27 | 505 | 116 |  | 2 | 523 |
| 113 |  | 2.28 | 563 | 117 |  | 1.55 | 484 |
| 114 |  | 2.11 | 509 | 118 |  | 1.9 | 495 |
| 115 |  | 2.21 | 537 | 119 |  | 2.04 | 569 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 120 |  | 1.77 | 536 | 124 |  | 2.47 | 561 |
| 121 |  | 2.53 | 554 | 125 |  | 2.01 | 553 |
| 122 |  | 2.09 | 509 | 126 |  | 2.01 | 510 |
| 123 |  | 2.13 | 549 | 127 |  | 1.83 | 496 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 128 |  | 2.09 | 569 | 132 |  | 2.39 | 529 |
| 129 |  | 1.94 | 480 | 133 |  | 1.66 | 501 |
| 130 |  | 2.1 | 480 | 134 |  | 1.67 | 499 |
| 131 |  | 2.4 | 552 | 135 |  | 1.83 | 511 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 136 |  | 2.12 | 553 | 140 |  | 2.19 | 513 |
| 137 |  | 2.32 | 529 | 141 |  | 2.05 | 587 |
| 138 |  | 2.03 | 527 | 142 |  | 2.43 | 595 |
| 139 |  | 2.28 | 485 | 143 |  | 2.34 | 517 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 144 |  | 3.07 | 558 | 148 |  | 2.28 | 527 |
| 145 |  | 1.91 | 480 | 149 |  | 2.4 | 547 |
| 146 |  | 2.39 | 534 | 150 |  | 3.28 | 615 |
| 147 |  | 2.13 | 555 | 151 |  | 1.81 | 496 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 152 |  | 2.17 | 494 | 156 |  | 2.09 | 557 |
| 153 |  | 2.16 | 545 | 157 |  | 1.28 | 529 |
| 154 |  | 1.71 | 499 | 158 |  | 2.52 | 547 |
| 155 |  | 1.91 | 496 | 159 |  | 1.75 | 499 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 160 |  | 1.71 | 499 | 164 |  | 2.25 | 537 |
| 161 |  | 1.95 | 525 | 165 |  | 2.27 | 543 |
| 162 |  | 1.83 | 554 | 166 |  | 1.79 | 469 |
| 163 |  | 1.72 | 525 | 167 |  | 2.01 | 553 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 168 |  | 1.92 | 466 | 172 |  | 2.49 | 565 |
| 169 |  | 2.2 | 535 | 173 |  | 2.03 | 583 |
| 170 |  | 2.11 | 529 | 174 |  | 2.03 | 557 |
| 171 |  | 1.9 | 557 | 175 |  | 1.8 | 495 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 176 |  | 2.19 | 521 | 180 |  | 2.53 | 547 |
| 177 |  | 1.99 | 510 | 181 |  | 2.01 | 555 |
| 178 |  | 2.2 | 635 | 182 |  | 2.97 | 599 |
| 179 |  | 2.16 | 535 | 183 |  | 1.82 | 480 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 184 |  | 2.19 | 511 | 188 |  | 2.47 | 545 |
| 185 |  | 2.43 | 551 | 189 |  | 1.88 | 539 |
| 186 |  | 2.41 | 567 | 190 |  | 1.79 | 537 |
| 187 |  | 1.97 | 553 | 191 |  | 0.92 | 470 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 192 |  | 1.86 | 532 | 196 |  | 2.11 | 569 |
| 193 |  | 2.09 | 515 | 197 |  | 1.87 | 509 |
| 194 |  | 2.18 | 521 | 198 |  | 2.14 | 521 |
| 195 |  | 2.3 | 516 | 199 |  | 2.09 | 520 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 200 |  | 2.19 | 552 | 204 |  | 2.24 | 573 |
| 201 |  | 2.15 | 498 | 205 |  | 2.1 | 539 |
| 202 |  | 2.11 | 529 | 206 |  | 2.49 | 591 |
| 203 |  | 2.28 | 552 | 207 |  | 1.77 | 541 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 208 |  | 2.08 | 541 | 212 |  | 1.98 | 510 |
| 209 |  | 2.08 | 486 | 213 |  | 2.17 | 553 |
| 210 |  | 2.11 | 515 | 214 |  | 1.72 | 503 |
| 211 |  | 1.74 | 541 | 215 |  | 2.14 | 605 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 216 |  | 1.98 | 512 | 220 |  | 2.56 | 597 |
| 217 |  | 1.76 | 552 | 221 |  | 1.91 | 524 |
| 218 |  | 2.06 | 575 | 222 |  | 2.51 | 581 |
| 219 |  | 1.97 | 525 | 223 |  | 3.18 | 561 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 224 |  | 2.26 | 514 | 228 |  | 1.97 | 544 |
| 225 |  | 2.43 | 537 | 229 |  | 2.81 | 551 |
| 226 |  | 1.96 | 518 | 230 |  | 2.81 | 565 |
| 227 |  | 2.35 | 581 | 231 |  | 1.76 | 481 |









| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 232 |  | 1.86 | 539 | 236 |  | 2.25 | 534 |
| 233 |  | 2.52 | 540 | 237 |  | 2.63 | 595 |
| 234 |  | 2.39 | 559 | 238 |  | 2.61 | 611 |
| 235 |  | 1.79 | 483 | 239 |  | 2.22 | 555 |





| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 240 |  | 2.34 | 517 | 244 |  | 2.61 | 579 |
| 241 |  | 1.93 | 466 | 245 |  | 3.04 | 599 |
| 242 |  | 1.77 | 495 | 246 |  | 2.4 | 595 |
| 243 |  | 2.13 | 479 | 247 |  | 2.33 | 521 |

| Ex. | Structure | t _R | MH+ | Ex. | Structure | t _R | MH+ |
|-----|---|----------------|-----|-----|--|----------------|-----|
| 248 |  | 1.97 | 539 | 252 |  | 2.31 | 517 |
| 249 |  | 2.74 | 520 | 253 |  | 2.1 | 544 |
| 250 |  | 2.15 | 545 | 254 |  | 2.35 | 554 |
| 251 |  | 2.08 | 493 | 255 |  | 1.88 | 553 |

| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 256 |  | 2.23 | 499 | 260 |  | 2.37 | 568 |
| 257 |  | 2.02 | 513 | 261 |  | 1.64 | 539 |
| 258 |  | 1.99 | 498 | 262 |  | 1.87 | 513 |
| 259 |  | 1.8 | 555 | 263 |  | 2.82 | 599 |

| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 264 |  | 1.65 | 499 | 268 |  | 1.65 | 513 |
| 265 |  | 2.66 | 625 | 269 |  | 2.04 | 509 |
| 266 |  | 2.09 | 523 | 270 |  | 0.75 | 469 |
| 267 |  | 2.08 | 523 | 271 |  | 2.66 | 577 |

| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|--|----------------|-----------------|
| 272 |  | 2.08 | 573 | 276 |  | 2.68 | 551 |
| 273 |  | 1.8 | 511 | 277 |  | 2.03 | 587 |
| 274 |  | 2.2 | 561 | 278 |  | 1.67 | 514 |
| 275 |  | 2.23 | 566 | 279 |  | 1.8 | 507 |

| Ex. | Structure | t _R | MH ⁺ | Ex. | Structure | t _R | MH ⁺ |
|-----|---|----------------|-----------------|-----|---|----------------|-----------------|
| 280 |  | 2.08 | 513 | 282 |  | 2.32 | 571 |
| 281 |  | 2 | 539 | 283 |  | 2.62 | 551 |

SEQUENCE LISTING

5 <110> Glaxo Group Limited

<120> Chemical Compounds

10 <130> PU4191

<140> to be assigned

<141> 2001-09-06

15 <150> 60/233,144

<151> 2000-09-18

<160> 5

20 <170> FastSEQ for Windows Version 4.0

<210> 1

<211> 11

<212> PRT

<213> Artificial Sequence

25 <220>

<223> modified polyhistidine tag

30 <400> 1

Met Lys Lys Gly His His His His His His Gly

1 5 10

35 <210> 2

<211> 25

<212> PRT

<213> Artificial Sequence

40 <220>

<223> biotinylated peptide comprising amino acids

675-699 of SRC-1

100

<400> 2
Cys Pro Ser Ser His Ser Ser Leu Thr Glu Arg His Lys Ile Leu His
1 5 10 15
Arg Leu Leu Gln Glu Gly Ser Pro Ser
5 20 25

<210> 3
<211> 24
10 <212> DNA
<213> Artificial Sequence

<220>
<223> mouse ABC1 (X75926) forward primer
15

<400> 3
aagggtttct ttgctcagat tgct 24

<210> 4
20 <211> 17
<212> DNA
<213> Artificial Sequence

<220>
25 <223> mouse ABC1 (X75926) reverse primer

<400> 4
tgccaaaggg tggcaca 17

30 <210> 5
<211> 25
<212> DNA
<213> Artificial Sequence

35 <220>
<223> mouse ABC1 (X75926) probe oligo


<400> 5
ccagctgtct ttgtttgcat tgccc 25

CLAIMS

That Which Is Claimed Is:

1. A compound of formula (I):

5



10

wherein:

X is OH or NH₂;

p is 0-6;

each R¹ and R² are the same or different and are each independently selected from the group consisting of H, C₁-alkyl, C₁-alkoxy and C₁-thioalkyl;

15

Z is CH or N;

when Z is CH, k is 0-4;

when Z is N, k is 0-3;

each R³ is the same or different and is independently selected from the group

20

consisting of halo, -OH, C₁-alkyl, C₂-alkenyl, C₁-alkoxy, C₂-alkenyloxy, -S(O)_aR⁶, -NR⁷R⁸, -COR⁶, COOR⁶, R¹⁰COOR⁶, OR¹⁰COOR⁶, CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, 5-6 membered heterocycle, nitro, and cyano;

a is 0, 1 or 2;

R⁶ is selected from the group consisting of H, C₁-alkyl, C₁-alkoxy and

25

C₂-alkenyl;

each R⁷ and R⁸ are the same or different and are each independently selected

from the group consisting of H, C₁-alkyl, C₂-alkenyl,

C₃-alkynyl;

R⁹ is selected from the group consisting of H, C₁-alkyl and -NR⁷R⁸;

30

R¹⁰ is C₁-alkyl;

n is 2-8;

q is 0 or 1;

R⁴ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkenyl, and alkenyloxy;

Ring A is selected from the group consisting of C₃₋₈cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;

each ring B is the same or different and is independently selected from the group

5 consisting of C₃₋₈cycloalkyl and aryl; and

pharmaceutically acceptable salts and solvates thereof.

2. The compound according to claim 1, wherein X is OH.

10 3. The compound according to any of claims 1-2, wherein p is 0 or 1.

4. The compound according to any of claims 1-2, wherein p is 1.

5. The compound according to any of claims 1-4, wherein each R¹ and R²
15 are the same or different and are each independently selected from the group consisting of H and C₁₋₈alkyl.

6. The compound according to any of claims 1-4, wherein R¹ and R² are each H.

20

7. The compound according to any of claims 1-6, wherein Z is CH.

8. The compound according to any of claims 1-7, wherein k is 0.

25 9. The compound according to any of claims 1-8, wherein R³ is selected from the group consisting of halo and C₁₋₈alkoxy.

10. The compound according to any of claims 1-9, wherein n is 2-4.

30 11. The compound according to any of claims 1-9, wherein q is 1.

12. The compound according to any of claims 1-11, wherein R⁴ is H or C₁₋₈alkyl.

13. The compound according to any of claims 1-12, wherein Ring A is aryl.

5

14. The compound according to any of claims 1-13, wherein Ring A is phenyl optionally substituted from 1 to 5 times with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸,
10 -OR¹⁰NR⁷R⁸, nitro, and cyano.

15. The compound according to any of claims 1-13, wherein Ring A is phenyl optionally substituted from 1 to 5 times with a substituent selected from the group consisting of halo, C₁₋₈alkyl, C₁₋₈alkoxy, and S(O)_aR⁶.

15

16. The compound according to any of claims 1-13, wherein Ring A is phenyl optionally substituted from 1 to 5 times with a substituent selected from the group consisting of F, Cl, -CF₃, -OCH₃, and -OCF₃.

20 17. The compound according to any of claims 1-16 wherein both Rings B are phenyl optionally substituted from 1 to 5 times with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano.

25

18. The compound according to any of claims 1-16 wherein both Rings B are cyclohexyl optionally substituted from 1 to 10 times with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹,
30 -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano.

19. The compound according to any of claims 1-16 wherein one Ring B is phenyl optionally substituted from 1 to 5 times with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano and the other Ring B is cyclohexyl optionally substituted from 1 to 10 times with a substituent selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano.
20. A compound selected from the group consisting of:
- 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}phenyl)acetamide,
- 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid,
- (3-{2-[(2,2-diphenylethyl)-(4-methoxybenzyl)amino]propoxy}phenyl)acetamide,
- (3-{2-[(2,2-diphenylethyl)-(4-methoxybenzyl)amino]propoxy}phenyl)acetic acid,
- 2-(3-{3-[[2,2-diphenylethyl](2-fluoro-4-methoxybenzyl)amino]propoxy}phenyl)acetamide,
- 2-(3-{3-[[2,4-dimethoxybenzyl](2,2-diphenylethyl)amino]propoxy}phenyl)acetamide,
- 2-[3-(3-{(2,2-diphenylethyl)[4-fluoro-2-(trifluoromethyl)benzyl]amino}propoxy)phenyl]acetamide,
- 2-(3-{3-[[2,3-dichlorobenzyl](2,2-diphenylethyl)amino]propoxy}phenyl)acetamide,
- 2-[3-(3-{(2,2-diphenylethyl)[3-(trifluoromethoxy)benzyl]amino}propoxy)phenyl]acetamide,
- 2-(3-{3-[[2,2-diphenylethyl](3-fluoro-4-methoxybenzyl)amino]propoxy}phenyl)acetamide,
- 2-(3-{3-[[2,5-dimethoxybenzyl](2,2-diphenylethyl)amino]propoxy}phenyl)acetamide,
- 2-[3-(3-{(2,2-diphenylethyl)[3-(trifluoromethyl)benzyl]amino}propoxy)phenyl]acetamide,
- 2-[3-(3-{(2,2-diphenylethyl)[2-fluoro-3-(trifluoromethyl)benzyl]amino}propoxy)phenyl]acetamide;

- Ethyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{2,2-diphenylethyl}amino]-1-piperidinecarboxylate;
3-{3-[(1-Benzoyl-4-piperidinyl)-(2,2-diphenylethyl)amino]propoxy}benzamide;
3-{3-[(1-Acetyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy}benzamide;
5 Benzyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{2,2-diphenylethyl}amino]-1-piperidinecarboxylate;
3-{3-[(2,2-Diphenylethyl)[1-(2-phenylethyl)-4-piperidinyl]amino}propoxy}benzamide;
Ethyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{2-cyclohexyl-2-phenylethyl}amino]-1-piperidinecarboxylate;
10 3-{3-[(1-Benzoyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-benzamide;
3-{3-[(1-Acetyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-benzamide;
tert-Butyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{2-cyclohexyl-2-phenylethyl}amino]-1-piperidinecarboxylate;
15 Benzyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{2-cyclohexyl-2-phenylethyl}amino]-1-piperidinecarboxylate;
3-{3-[(1-Benzyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-benzamide;
20 Ethyl 4-[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl]{2,2-diphenylethyl}amino]-1-piperidinecarboxylate;
2-(3-{3-[(1-Benzoyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy}phenyl)-acetamide;
2-(3-{3-[(1-Acetyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy}phenyl)-acetamide;
25 *tert*-Butyl 4-[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl]{2,2-diphenylethyl}amino]-1-piperidinecarboxylate;
Benzyl 4-[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl]{2,2-diphenylethyl}amino]-1-piperidinecarboxylate;
30 2-[3-(3-{(2,2-Diphenylethyl)[1-(2-phenylethyl)-4-piperidinyl]amino}propoxy)phenyl]-acetamide;

- 2-(3-{3-[(1-Benzoyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-phenyl)acetamide;
- 2-(3-{3-[(1-Acetyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}-phenyl)acetamide;
- 5 Benzy-4-[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl]{(2-cyclohexyl-2-phenylethyl)amino}-1-piperidinecarboxylate;
- 3-{3-[(3-Cyanobenzyl)(2,2-diphenylethyl)amino]propoxy}benzamide;
- 3-{3-[Cyclohexyl(2,2-diphenylethyl)amino]propoxy}benzamide;
- 4-[[3-[3-(Aminocarbonyl)phenoxy]propyl]{(2,2-diphenylethyl)amino}-1-
- 10 piperidinecarboxamide;
- 3-{3-[(1,3-Benzodioxol-4-ylmethyl)(2,2-diphenylethyl)amino]propoxy}benzamide;
- 3-{3-[(3,4-Dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}benzamide;
- 3-{3-[(4-Cyanobenzyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}benzamide;
- 3-{3-[(4-Cyanobenzyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy}benzamide;
- 15 2-(3-{3-[Cyclohexyl(2,2-diphenylethyl)amino]propoxy}phenyl)acetamide;
- 2-(3-{3-[(3,4-Dimethoxybenzyl)(2,2-diphenylethyl)amino]propoxy}phenyl)acetamide;
- 3-{3-[(2-Cyclohexyl-2-phenylethyl)(3,4-dimethoxybenzyl)amino]propoxy}benzamide;
- 3-{3-[(2,6-Dichlorobenzyl)(2,2-diphenylethyl)amino]propoxy}benzamide;
- 3-[[3-[3-(Aminocarbonyl)phenoxy]propyl]{(2,2-diphenylethyl)amino}methyl}benzoic
- 20 acid;
- 4-[[3-[3-(Aminocarbonyl)phenoxy]propyl]{(2,2-diphenylethyl)amino}methyl}benzoic acid;
- 3-(3-{(2,2-Diphenylethyl)[(5-methoxy-1*H*-indol-3-yl)methyl]amino}propoxy)-benzamide;
- 25 3-{3-[(2,2-Diphenylethyl)(4-methoxybenzyl)amino]propoxy}benzamide;
- 3-{3-[[[(1-Acetyl-1*H*-indol-3-yl)methyl](2,2-diphenylethyl)amino]propoxy}benzamide;
- Methyl 4-[[3-[3-(aminocarbonyl)phenoxy]propyl]{(2,2-diphenylethyl)amino}methyl}-benzoate;
- 3-{3-[(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)(2,2-diphenylethyl)amino]propoxy}-
- 30 benzamide;
- 3-{3-[(2,2-Diphenylethyl)(4-pyridinylmethyl)amino]propoxy}benzamide;

- 2-(3-{3-[(2-Cyclohexyl-2-phenylethyl)(3,4-difluorobenzyl)amino]propoxy}phenyl)acetamide;
- 2-(3-{3-(2,2-Diphenylethyl)[[(6-chloro-1,3-benzodioxol-5-yl)methyl]amino]propoxy}-phenyl)acetamide;
- 5 2-(3-{3-[(2,2-Diphenylethyl)(cyclohexylmethyl)amino]propoxy}phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)(bicyclo[2.2.1]hept-5-en-2-ylmethyl)amino]propoxy}-phenyl) acetamide;
- 2-(3-{3-[(2,2-diphenylethyl)(2,4-dimethoxy-5-pyrimidinyl) methyl]amino]propoxy}phenyl) acetamide;
- 10 2-(3-{3-[(2,2-Diphenylethyl)(5-isopropyl-3-methyl-4-isoxazolyl)methyl]amino]-propoxy}phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)(3,4-dihydro-2*H*-pyran-2-ylmethyl)amino]propoxy}-phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)(4-chloro-1*H*-pyrazol-3-yl)methyl]amino]propoxy}-phenyl) acetamide;
- 15 2-(3-{3-[(2,2-Diphenylethyl)()[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino]-propoxy}phenyl) acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethyl]amino]-propoxy}phenyl) acetamide;
- 20 2-(3-{3-[(2,2-Diphenylethyl)(3-cyclohexen-1-ylmethyl)amino]propoxy}phenyl)acetamide;
- 2-[3-(3-{(2,2-Diphenylethyl)[(2*E*)-3-phenyl-2-propenyl]amino}propoxy)phenyl]acetamide;
- Ethyl 2-{[{3-[3-(2-amino-2-oxoethyl)phenoxy]propyl}{(2,2-diphenylethyl)amino]-methyl}cyclopropanecarboxylate;
- 25 2-(3-{3-[(2,2-diphenylethyl)(1-cyclohexen-1-ylmethyl)amino]propoxy} phenyl)acetamide;
- 2-(3-{3-[(2,2-Diphenylethyl)(1*H*-benzimidazol-2-ylmethyl)amino]propoxy}phenyl)acetamide;
- 30 2-(3-{3-[(2,2-Diphenylethyl)[(1,3-dimethyl-2-oxo-2,3-dihydro-1*H*-benzimidazol-5-yl)methyl]amino]propoxy}phenyl) acetamide; and
- 2-(3-{3-[(2,2-Diphenylethyl)(2-pyrrolidinylmethyl)amino]propoxy}phenyl) acetamide;

and pharmaceutically acceptable salts and solvates thereof.

21. 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-
diphenylethyl)amino]propoxy}phenyl)acetic acid and pharmaceutically acceptable
5 salts and solvates thereof.

22. A pharmaceutical composition comprising a compound according to
any of claims 1-21.

10 23. The pharmaceutical composition according to claim 24 further
comprising a pharmaceutically acceptable carrier or diluent.

24. A method for the prevention or treatment of an LXR mediated disease
or condition comprising administering a therapeutically effective amount of a
15 compound according to any of claims 1-21.

25. The method according to claim 24, wherein said LXR mediated disease
or condition is cardiovascular disease.

20 26. The method according to claim 24, wherein said LXR mediated disease
or condition is atherosclerosis.

27. A method for increasing reverse cholesterol transport, said method
comprising administering a therapeutically effective amount of a compound
25 according to any of claims 1-21.

28. A method for inhibiting cholesterol absorption, said method comprising
administering a therapeutically effective amount of a compound according to any of
claims 1-21.

30

29. A method for increasing HDL-cholesterol, said method comprising administering a therapeutically effective amount of a compound according to any of claims 1-21.

5 30. A method for decreasing LDL-cholesterol, said method comprising administering a therapeutically effective amount of a compound according to any of claims 1-21.

31. A radiolabeled compound according to any of claims 1-21.

10 32. The radiolabeled compound of claim 32, wherein said compound is tritiated.

33. A method for identifying compounds which interact with LXR, said method comprising the step of specifically binding the radiolabeled compound of
15 claim 31 to the ligand binding domain of LXR.

34. The method according to claim 33, further comprising the step of adding a compound to be tested, and measuring any decrease in the specific binding of the radiolabeled compound.

20

35. A method for identifying compounds which upregulate expression of ABC1, said method comprising the step of specifically binding the radiolabeled compound of claim 31 to the ligand binding domain of LXR.


25 36. A compound identified using the method of claim 33.

37. A method for the treatment or prevention of an LXR mediated disease or condition, said method comprising administering a therapeutically effective amount of a compound which is identified by the method of claim 33.

30

38. A method for the treatment or prevention of cardiovascular disease, said method comprising administering a therapeutically effective amount of a compound which is identified by the method of claim 33.

- 5 39. A process for preparing a compound according to any of claims 1-21, said process comprising reacting a solid phase-bound compound of formula (V):




wherein SP is solid phase and X^0 is $-O-$ or $-NH-$;
with a compound of formula (VIII):



40. The process according to claim 39 further comprising the step of cleaving the compound of formula (I) from the solid phase.

- 20 41. A process for preparing a compound according to any of claims 1-21, said process comprising the steps of:

a) reacting a compound of formula (IV-A):




wherein X^1 is OR^{16} or NH_2 , where R^{16} is a protecting group;

111

with a compound of formula (IX):



to prepare a compound of formula (I-A):




and

b) in the embodiment wherein X^1 is OR^{16} , saponifying the compound of formula (I-A) to produce the compound of formula (I).

15

42. The process according to any of claims 39-41 further comprising the step of converting a compound of formula (I) to a pharmaceutically acceptable salt or solvate thereof.

20 43. A compound of formula I-A:



25 wherein:

X^1 is OR^{16} or NH_2 , where R^{16} is a protecting group;

p is 0-6;

each R^1 and R^2 are the same or different and are each independently selected from the group consisting of H, C_{1-8} alkyl, C_{1-8} alkoxy and C_{1-8} thioalkyl;

30 Z is CH or N;

when Z is CH, k is 0-4;

when Z is N, k is 0-3;

- each R³ is the same or different and is independently selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, -S(O)_aR⁶, -NR⁷R⁸, -COR⁶, COOR⁶, R¹⁰COOR⁶, OR¹⁰COOR⁶, CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, 5-6 membered heterocycle, nitro, and cyano;
- 5 a is 0, 1 or 2;
- R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl;
- each R⁷ and R⁸ are the same or different and are each independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl,
- 10 C₃₋₈alkynyl;
- R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸;
- R¹⁰ is C₁₋₈alkyl;
- n is 2-8;
- q is 0 or 1;
- 15 R⁴ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkenyl, and alkenyloxy;
- Ring A is selected from the group consisting of C₃₋₈cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;
- each ring B is the same or different and is independently selected from the group consisting of C₃₋₈cycloalkyl and aryl; and
- 20 pharmaceutically acceptable salts and solvates thereof.

44. A compound according to any of claims 1-21 for use in therapy.

45. A compound according to any of claims 1-21 for use in the prevention
- 25 or treatment of an LXR mediated disease or condition.

46. A compound according to any of claims 1-21 for use in the prevention or treatment of cardiovascular disease.

- 30 47. A compound according to any of claims 1-21 for use in the prevention or treatment of atherosclerosis.

48. A compound according to any of claims 1-21 for increasing reverse cholesterol transport.
- 5 49. A compound according to any of claims 1-21 for inhibiting cholesterol absorption.
50. A compound according to any of claims 1-21 for increasing HDL-cholesterol.
- 10 51. A compound according to any of claims 1-21 for decreasing LDL-cholesterol.
52. Use of a compound according to any of claims 1-21 for the preparation of a medicament for the prevention or treatment of an LXR mediated disease or
15 condition.
53. Use of a compound according to any of claims 1-21 for the preparation of a medicament for the prevention or treatment of cardiovascular disease.
- 20 54. Use of a compound according to any of claims 1-21 for the preparation of a medicament for the prevention or treatment of atherosclerosis.
55. Use of a compound according to any of claims 1-21 for the preparation of a medicament for increasing reverse cholesterol transport.
25
56. Use of a compound according to any of claims 1-21 for the preparation of a medicament for inhibiting cholesterol absorption.
57. Use of a compound according to any of claims 1-21 for the preparation
30 of a medicament for increasing HDL-cholesterol.

58. Use of a compound according to any of claims 1-21 for the preparation of a medicament for decreasing LDL-cholesterol.

59. A pharmaceutical composition comprising a compound according to
5 any of claims 1-21 for use in the prevention or treatment of an LXR mediated disease or condition.

SEQUENCE LISTING

<110> Glaxo Group Limited

<120> Chemical Compounds

5

<130> PU4191

<140> to be assigned

10 <141> concurrently herewith

<150> 60/233,144

<151> 2000-09-18

15 <160> 5

<170> FastSEQ for Windows Version 4.0

<210> 1

20 <211> 11

<212> PRT

<213> Artificial Sequence

<220>

25 <223> modified polyhistidine tag

<400> 1

Met Lys Lys Gly His His His His His His Gly

1 5 10

30

<210> 2

<211> 25

<212> PRT

35 <213> Artificial Sequence

<220>

<223> biotinylated peptide comprising amino acids
675-699 of SRC-1

5

<400> 2

Cys Pro Ser Ser His Ser Ser Leu Thr Glu Arg His Lys Ile Leu His

1

5

10

15

Arg Leu Leu Gln Glu Gly Ser Pro Ser

10

20

25

<210> 3

<211> 24

15

<212> DNA

<213> Artificial Sequence

<220>

<223> mouse ABC1 (X75926) forward primer

20

<400> 3

aagggtttct ttgctcagat tgtc

24

<210> 4

25

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

30

<223> mouse ABC1 (X75926) reverse primer

<400> 4

tgccaaaggg tggcaca

17

35

<210> 5

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> mouse ABC1 (X75926) probe oligo

5 <400> 5

ccagctgtct ttgtttgcat tgccc

25

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
28 March 2002 (28.03.2002)

(10) International Publication Number
WO 02/024632 A3

PCT

- (51) International Patent Classification⁷: **C07C 235/34**,
217/58, 217/22, 235/46, C07D 209/16, 213/38, 211/26,
261/08, A61K 31/165, 31/19, 31/33, A61P 9/10
- (21) International Application Number: PCT/US01/27622
- (22) International Filing Date:
6 September 2001 (06.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/233,144 18 September 2000 (18.09.2000) US
- (71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **COLLINS, Jon, Loren** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **FIVUSH, Adam, M** [US/US]; 12023 Quarry Court, Fishers, IN 46038 (US). **MALONEY, Patrick, Reed** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **STEWART, Eugene, L** [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **WILLSON, Timothy, Mark** [GB/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
11 July 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR



(57) Abstract: The invention relates to a compound of formula (I), wherein all variables are as defined herein, and pharmaceutically acceptable salts or solvates thereof. The compounds of formula (I) are useful as LXR agonists.

WO 02/024632 A3

INTERNATIONAL SEARCH REPORT

In tional Application No
PCT/US 01/27622

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C235/34 C07C217/58 C07C217/22 C07C235/46 C07D209/16
C07D213/38 C07D211/26 C07D261/08 A61K31/165 A61K31/19
A61K31/33 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | EP 0 558 062 A (ONO PHARMACEUTICAL CO) 1 September 1993 (1993-09-01) page 2; claim 1; table 4 --- | 1,52-59 |
| A,P | WO 00 54759 A (TULARIK INC) 21 September 2000 (2000-09-21) abstract; figure 1 --- | 1,52-59 |
| A,P | WO 01 60818 A (TULARIK INC) 23 August 2001 (2001-08-23) claims 1-27 ----- | 1,52-59 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *I* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

11 April 2002

Date of mailing of the international search report

18/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-19, 22, 23, 31, 32, 36, 39-59 all partly

Present claims 1-19, 22, 23, 31, 32, 36, 39-59 relate to an extremely large number of possible compounds, methods, processes or pharmaceutical compositions. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds, methods, processes or pharmaceutical compositions claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds according to formula (I) of claim 1 with the following restriction:

n is 3 and B = phenyl or cyclohexyl.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In tional Application No

PCT/US 01/27622

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| EP 0558062 | A | 01-09-1993 | AT 152712 T | 15-05-1997 |
| | | | CA 2090283 A1 | 29-08-1993 |
| | | | DE 69310413 D1 | 12-06-1997 |
| | | | DE 69310413 T2 | 02-10-1997 |
| | | | DK 558062 T3 | 02-06-1997 |
| | | | EP 0558062 A2 | 01-09-1993 |
| | | | ES 2103989 T3 | 01-10-1997 |
| | | | GR 3023344 T3 | 29-08-1997 |
| | | | JP 3162532 B2 | 08-05-2001 |
| | | | JP 6056744 A | 01-03-1994 |
| | | | JP 2000086635 A | 28-03-2000 |
| | | | KR 187325 B1 | 15-05-1999 |
| | | | US 5378716 A | 03-01-1995 |
| | | | US 5536736 A | 16-07-1996 |
| | | | US 5703099 A | 30-12-1997 |
| | | | US 5935985 A | 10-08-1999 |
| WO 0054759 | A | 21-09-2000 | AU 3627300 A | 04-10-2000 |
| | | | EP 1161233 A2 | 12-12-2001 |
| | | | WO 0054759 A2 | 21-09-2000 |
| | | | US 6316503 B1 | 13-11-2001 |
| WO 0160818 | A | 23-08-2001 | WO 0160818 A1 | 23-08-2001 |
| | | | AU 3596000 A | 27-08-2001 |